

Shandong Weigao Group Medical Polymer Company Limited* 山東威高集團醫用高分子製品股份有限公司

(a joint stock limited company incorporated in the People's Republic of China with limited liability)
(在中華人民共和國註冊成立的股份有限公司)
(Stock Code 股票號碼: 1066)

* For identification purposes only
僅供識別

Interim Report 2025 中期報告

WEGO 威高

SUMMARY

For the six months ended 30 June 2025 (the “**Period**”), the unaudited revenue of Shandong Weigao Group Medical Polymer Company Limited (the “**Company**”) and its subsidiaries (the “**Group**”) was approximately RMB6,644,048,000 (same period in 2024: approximately RMB6,635,688,000), representing an increase of approximately 0.1% as compared with the same period last year, the unaudited net profit attributable to the owners of the Company was approximately RMB1,008,317,000 (same period in 2024: approximately RMB1,107,549,000), representing a decrease of approximately 9.0% as compared with the same period last year.

Net profit attributable to the owners of the Company (excluding extraordinary items) was approximately RMB967,095,000, representing a decrease of approximately 12.7% as compared to comparable figure (same period in 2024: approximately RMB1,107,549,000) over the same period last year.

The board of directors (the “**Board**”) proposed the distribution of an interim dividend for the six months ended 30 June 2025 of RMB0.0969 per share (same period in 2024: RMB0.0919 per share). The proposal is subject to the approval of shareholders of the Company (the “**Shareholders**”) at the forthcoming extraordinary general meeting.

概要

山東威高集團醫用高分子製品股份有限公司(「**本公司**」)及其附屬公司(「**本集團**」)截至二零二五年六月三十日止六個月(「**期間**」)，未經審核之收入約人民幣6,644,048,000元(二零二四年同期：約人民幣6,635,688,000元)，較去年同期增長約0.1%，未經審核之本公司擁有人應佔純利約人民幣1,008,317,000元(二零二四年同期：約人民幣1,107,549,000元)，較去年同期下跌約9.0%。

不計特殊項目的本公司擁有人應佔純利約人民幣967,095,000元，較去年同期可比數(二零二四年同期：約人民幣1,107,549,000元)下跌約12.7%。

董事會(「**董事會**」)建議派發截至二零二五年六月三十日止六個月之中期股息每股人民幣0.0969元(二零二四年同期：每股人民幣0.0919元)。該建議須經本公司股東(「**股東**」)在即將舉行的股東特別大會上批准後，方可作實。

UNAUDITED CONDENSED CONSOLIDATED INTERIM RESULTS

The Board is pleased to announce the unaudited condensed consolidated interim results of the Group for the six months ended 30 June 2025, together with the unaudited comparative figures for the same period* in 2024 as follows:

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

未經審核簡明綜合中期業績

董事會欣然宣佈本集團於截至二零二五年六月三十日止六個月未經審核簡明綜合中期業績，連同二零二四年同期*未經審核比較數字如下：

未經審核簡明綜合全面收益表

		Unaudited 未經審核		
		For the six months ended 30 June		
		截至六月三十日止六個月		
		Notes 附註		
			2025 二零二五年 RMB'000 人民幣千元	2024 二零二四年 RMB'000 人民幣千元
Revenue	收入	3	6,644,048	6,635,688
Cost of sales	銷售成本		(3,340,540)	(3,259,245)
Gross profit	毛利		3,303,508	3,376,443
Other income, gains and losses	其他收入、收益及虧損		117,158	191,376
Impairment losses under expected credit loss model	預期信貸虧損模型下之減值虧損		(12,595)	(7,490)
Selling expenses	銷售開支		(1,179,675)	(1,229,556)
Administration expenses	行政開支		(619,961)	(574,773)
Research and development expenses	研發開支		(315,532)	(301,613)
Finance costs	融資成本	4	(116,773)	(128,776)
Share of results of associates	應佔聯營公司業績		53,233	47,633
Share of results of joint ventures	應佔合營企業業績		(3,459)	(6,865)
Profit before taxation	除稅前溢利	5	1,225,904	1,366,379
Income tax expense	所得稅開支	6	(168,919)	(212,809)
Profit for the Period	期間內溢利		1,056,985	1,153,570

* The comparative figures for the prior period have been represented to reclassify certain items, mainly staff costs within selling and administrative expenses by considering the functionality of those staffs, to align with current period's presentation. This reclassification has been made to ensure that the consolidated financial statements provide relevant, comparable, and understandable information to stakeholders. The reclassification does not affect the Group's financial performance or total expenses for the period presented.

上期的比較數字已作重新呈列，以按職能屬性重新分類若干項目（主要是銷售及行政開支內的員工成本），以符合本期的呈列方式。重新分類乃為確保綜合財務報表能向利害關係人提供相關、可比且易於理解的資料。重新分類並不影響本集團於呈列期間的財務表現或總支出。

Unaudited
未經審核
For the six months ended
30 June
截至六月三十日止六個月

			2025 二零二五年 RMB'000 人民幣千元	2024 二零二四年 RMB'000 人民幣千元
		Notes 附註		
Other comprehensive income	其他全面收入			
Exchange difference on translation of foreign operations	換算海外業務產生匯兌差額		(66,421)	17,077
Total comprehensive income for the Period	期間內全面收入總額		990,564	1,170,647
Profit for the Period attributable to:	期間內溢利下列各項應佔：			
Owners of the Company	本公司擁有人		1,008,317	1,107,549
Non-controlling interests	非控股權益		48,668	46,021
			1,056,985	1,153,570
Total comprehensive income attributable to:	全面收入總額下列各項應佔：			
Owners of the Company	本公司擁有人		944,512	1,125,269
Non-controlling interests	非控股權益		46,052	45,378
			990,564	1,170,647
			RMB 人民幣	RMB 人民幣
Earnings per share (basic)	每股盈利 (基本)	8	0.22	0.25
Earnings per share (diluted)	每股盈利 (攤薄)	8	0.22	0.24

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION **未經審核簡明綜合財務狀況表**

			As at 30 June 2025 於 二零二五年 六月三十日 RMB'000 人民幣千元 Unaudited 未經審核	As at 31 December 2024 於 二零二四年 十二月三十一日 RMB'000 人民幣千元 Audited 已審核
		<i>Notes 附註</i>		
Non-current assets	非流動資產			
Property, plant and equipment	物業、廠房及設備	9	6,846,633	6,533,346
Right-of-use assets	使用權資產		523,497	550,771
Investment properties	投資物業		97,889	122,023
Goodwill	商譽		3,761,214	3,830,629
Deposits paid for acquiring property, plant and equipment	就收購物業、廠房及設 備之已付按金		123,399	258,356
Intangible assets	無形資產		1,192,959	1,304,780
Interests in associates	於聯營公司的權益		1,729,574	1,604,557
Interests in joint ventures	於合營企業的權益		308,805	311,068
Financial assets at fair value through profit or loss	按公平值計入損益計量 之金融資產		72,267	72,987
Deferred tax assets	遞延稅項資產		220,217	248,543
Finance lease receivables	應收融資租賃款項		8,672	12,970
Loan receivables	應收貸款		503,434	413,391
Prepayments	預付款項	11	49,397	53,888
			15,437,957	15,317,309

			As at 30 June 2025 於 二零二五年 六月三十日 RMB'000 人民幣千元 Unaudited 未經審核	As at 31 December 2024 於 二零二四年 十二月三十一日 RMB'000 人民幣千元 Audited 已審核
		Notes 附註		
Current assets	流動資產			
Inventories	存貨	10	2,284,388	2,528,425
Loan receivables	應收貸款		236,722	314,427
Trade and other receivables	應收貿易賬款及其他應收款項	11	8,196,613	7,832,235
Financial assets at fair value through profit or loss	按公平值計入損益計量之金融資產		423,202	230,701
Debt instruments at fair value through other comprehensive income	按公平值計入其他全面收益計量之債務工具		284,002	310,797
Finance lease receivables	應收融資租賃款項		9,956	50,556
Pledged/restricted bank deposits	已抵押／受限制銀行存款	12	324,179	395,089
Bank balances and cash	銀行結餘及現金	13	8,945,180	7,780,310
			20,704,242	19,442,540
Current liabilities	流動負債			
Trade and other payables	應付貿易賬款及其他應付款項	14	4,203,873	4,294,068
Contract liabilities	合約負債		333,507	349,943
Borrowings	借款		858,498	1,202,862
Taxation payable	應付稅項		105,906	178,792
Deferred income	遞延收入		8,324	9,053
Lease liabilities	租賃負債		36,725	38,937
Provisions	撥備		9,183	6,849
			5,556,016	6,080,504
Net current assets	流動資產淨額		15,148,226	13,362,036
Total assets less current liabilities	總資產減流動負債		30,586,183	28,679,345

		As at 30 June 2025 於 二零二五年 六月三十日 RMB'000 人民幣千元 Unaudited 未經審核	As at 31 December 2024 於 二零二四年 十二月三十一日 RMB'000 人民幣千元 Audited 已審核
		Notes 附註	
Capital and reserves	資本及儲備		
Share capital	股本		457,063
Reserves	儲備		23,647,480
Equity attributable to owners of the Company	本公司擁有人應佔權益		24,104,543
Non-controlling interests	非控股權益		1,590,314
Total equity	權益總額	15	25,694,857
Non-current liabilities	非流動負債		
Borrowings	借款		3,488,176
Bonds payable	應付債券		997,547
Trade and other payables	應付貿易賬款及 其他應付款項	14	122,493
Deferred income	遞延收入		59,002
Deferred tax liabilities	遞延稅項負債		55,915
Contract liabilities	合約負債		5,547
Lease liabilities	租賃負債		131,621
Provisions	撥備		31,025
			4,891,326
			30,586,183

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOW **未經審核簡明綜合現金流量表**

		Unaudited 未經審核 For the six months ended 30 June 截至六月三十日止六個月	
		2025 二零二五年 RMB'000 人民幣千元	2024 二零二四年 RMB'000 人民幣千元
Net cash inflow from operating activities	經營業務之現金流入淨額	881,573	1,022,774
Net cash outflow from investing activities	投資活動之現金流出淨額	(1,556,046)	(447,281)
Net cash before financing activities	融資前現金淨額	(674,473)	575,493
Net cash inflow (outflow) from financing activities	融資活動之現金流入 (流出) 淨額	833,293	(261,714)
Net increase in cash and cash equivalents	現金及現金等價物淨增加額	158,820	313,779
Cash and cash equivalents as at the beginning of the Period	於期間初之現金及現金等價物	4,942,882	4,797,461
Effect of foreign exchange rate changes	外匯匯率變動的影響	(3,696)	3,841
Cash and cash equivalents as at the end of the Period	於期間末之現金及現金等價物	5,098,006	5,115,081

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY **未經審核簡明綜合權益變動表**

		Unaudited 未經審核 For the six months ended 30 June 截至六月三十日止六個月	
		2025 二零二五年 RMB'000 人民幣千元	2024 二零二四年 RMB'000 人民幣千元
Balance as at 1 January	於一月一日之餘額	23,751,643	22,449,121
Net profit for the Period	期間內純利	1,008,317	1,107,549
Dividends recognised as distribution	確認為分派的股息	(555,879)	(425,093)
Share-based payments	以股份為基礎付款	10,805	17,592
Repurchase of shares of subsidiaries under a share incentive scheme	根據股份激勵計劃回購 附屬公司股份	(3,903)	(80,983)
Repurchase of shares of the Company	回購本公司股份	(41,339)	–
Repurchase of shares of a subsidiary	回購一間附屬公司股份	–	(10,117)
Acquired interest in subsidiary from non- controlling shareholder	自非控股股東收購的附屬公司 權益	(1,296)	–
Exchange differences arising on translation of foreign operations	換算海外業務產生之匯兌差額	(63,805)	17,720
Balance as at 30 June	於六月三十日之餘額	24,104,543	23,075,789

NOTES:

1. Overview

The Company was incorporated as a joint stock company with limited liability on 28 December 2000 in Shandong Province, the People's Republic of China (the “**PRC**”) under the Company Law of the PRC and listed on the GEM of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) in February 2004 and migrated to the main board in the Stock Exchange in July 2010. The ultimate holding company of the Company is Weihai Weigao International Medical Investment Holding Co Ltd* (威海威高國際醫療投資控股有限公司), a company registered in the PRC with limited liability. Its ultimate controlling shareholder is Mr. Chen Xue Li. The address of the registered office and principal place of business of the Company is No. 1, Wei Gao Road, Weihai, Shandong Province, PRC.

The Company and its subsidiaries are principally engaged in the research and development, production and sale of medical device products, orthopaedic products, interventional products, pharma packaging products and blood management products, and operate financing business. The unaudited condensed consolidated financial statements are presented in Renminbi (“**RMB**”), which is the functional currency of the Company.

附註：

1. 概述

本公司為根據中華人民共和國（「**中國**」）公司法於二零零零年十二月二十八日在中國山東省註冊成立的股份有限公司，其於二零零四年二月於香港聯合交易所有限公司（「**聯交所**」）GEM上市，並於二零一零年七月轉往聯交所主板上市。本公司最終控股公司為威海威高國際醫療投資控股有限公司(Weihai Weigao International Medical Investment Holding Co Ltd)*，其為於中國註冊的有限責任公司。其最終控股人士為陳學利先生。本公司之註冊辦事處及主要營業地點為中國山東省威海威高路1號。

本公司及其附屬公司主要從事研究及開發、生產及銷售醫療器械、骨科產品、介入產品、藥品包裝產品及血液管理產品，及經營融資業務。未經審核簡明綜合財務報表以本公司的功能貨幣人民幣（「**人民幣**」）呈列。

NOTES: (Continued)

2. Basis of preparation and principal accounting policies

The condensed consolidated financial statements have been prepared in accordance with Hong Kong Accounting Standard 34 (“**HKAS 34**”) “Interim Financial Reporting” issued by the Hong Kong Institute of Certified Public Accountants as well as the applicable disclosure requirements of Appendix 16 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The condensed consolidated financial statements have been prepared on the historical cost basis, except for certain financial instruments, which are measured at fair value, as appropriate.

Other than the accounting policies resulting from application of new and amendments to Hong Kong Financial Reporting Standards (“**HKFRSs**”), the accounting policies and methods of computation used in the condensed consolidated financial statements for the six months ended 30 June 2025 are the same as those presented in the Group’s annual consolidated financial statements for the year ended 31 December 2024.

附註：(續)

2. 編製基準和主要會計政策

簡明綜合財務報表乃根據由香港會計師公會頒佈之香港會計準則第34號（「**香港會計準則第34號**」）「中期財務報告」以及香港聯合交易所有限公司證券上市規則附錄十六之適用披露規定編製。

除按公平值計量（倘適用）之若干金融工具外，簡明綜合財務報表按歷史成本基準編製。

除應用新訂香港財務報告準則（「**香港財務報告準則**」）及其修訂本引致之會計政策外，截至二零二五年六月三十日止六個月的簡明綜合財務報表中採用的會計政策及計算方法與本集團於截至二零二四年十二月三十一日止年度的年度綜合財務報表所呈列者相同。

NOTES: (Continued)

2. Basis of preparation and principal accounting policies (Continued)

Application of amendments to HKFRS Accounting Standards

In the current interim period, the Group has applied the following amendment to HKFRS Accounting Standards issued by the HKICPA, for the first time, which is mandatorily effective for the Group's annual period beginning on 1 January 2025 for the preparation of the Group's condensed consolidated financial statements:

Amendments to	Lack of Exchangeability
IAS 21	

The application of the amendment to HKFRS Accounting Standards in the current interim period has had no material impact on the Group's financial positions and performance for the current and prior periods and/or on the disclosures set out in these condensed consolidated financial statements.

附註：(續)

2. 編製基準和主要會計政策 (續)

應用香港財務報告準則會計準則修訂本

於本中期間，本集團已首次應用下列由香港會計師公會頒佈之香港財務報告準則會計準則修訂本，用於編製本集團之簡明綜合財務報表，相關修訂本於二零二五年一月一日開始之本集團年度期間強制生效：

國際會計準則	缺乏可兌換性
第21號 (修訂本)	

於本中期間應用香港財務報告準則會計準則修訂本對本集團當期及過往期間之財務狀況以及表現及／或對該等簡明綜合財務報表所載之披露並無重大影響。

NOTES: (Continued)

3. Revenue and segment information

The Group is principally engaged in the research and development, production and sale of medical device products, orthopaedic products, interventional products, pharma packaging products, blood management products, and operate finance lease and factoring businesses in the PRC.

For management purposes, the Group is currently organised into six operating divisions – medical device, orthopaedic, interventional, pharma packaging, blood management and others. These divisions are segmented on the basis of internal reporting of the Group that are regularly reviewed by the chief operating decision maker for allocating resources to the segments and assessing their performance.

附註：(續)

3. 收入和分部資料

本集團主要從事研發、生產及銷售醫療器械產品、骨科產品、介入產品、藥品包裝產品、血液管理產品，及主要於中國經營融資租賃及保理業務。

就管理而言，本集團目前分為六個經營分部：醫療器械、骨科、介入、藥品包裝、血液管理及其他。該等部門乃按本集團各部的內部呈報基準劃分，定期由主要營運決策者審核，以分配資源至分部並評估其表現。

NOTES: (Continued)**3. Revenue and segment information**
(Continued)

The principal activities of the Group's operating segments are as follows:

- | | |
|------------------|--|
| Medical device | — production and sale of clinical care, anesthesia and surgical related products, interventional imaging products and medical testing devices. |
| Orthopaedic | — production and sale of orthopaedic products. |
| Interventional | — production and sale of tumour and blood vessel interventional instruments. |
| Pharma packaging | — production and sale of pre-filled syringes, flushing syringes and automatic dosing device products. |
| Blood management | — production and sale of blood bag products, blood transfusion equipment and blood irradiators. |
| Others | — finance lease and factoring businesses. |

附註：(續)**3. 收入和分部資料 (續)**

本集團經營分部的主要業務如下：

- | | |
|------|--------------------------------------|
| 醫療器械 | — 生產及銷售臨床護理、麻醉及手術相關產品、影像介入產品及醫學檢驗器械。 |
| 骨科 | — 生產及銷售骨科產品。 |
| 介入 | — 生產及銷售腫瘤、血管介入器械。 |
| 藥品包裝 | — 生產及銷售預灌封注射器、沖管注射器以及自動給藥裝置產品。 |
| 血液管理 | — 生產及銷售血袋產品、輸血設備及血液輻照儀等。 |
| 其他 | — 融資租賃及保理業務。 |

NOTES: (Continued)**3. Revenue and segment information**
(Continued)

The segment information and results of those businesses are as follows:

For the six months ended 30 June 2025 (Unaudited)**附註：(續)****3. 收入和分部資料 (續)**

該等業務的分佈資料與業績如下：

截至二零二五年六月三十日止六個月 (未經審核)

		Medical device 醫療器械	Orthopaedic 骨科	Interventional 介入	Pharma packaging 藥品包裝	Blood management 血液管理	Others 其他	Eliminations 撤減	Total 合計
		RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
		人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元
Revenue	收益								
External sales	外部銷售	3,300,160	732,864	990,265	1,166,495	454,264	-	-	6,644,048
Inter-segment sales	內部分部銷售	52,041	-	-	-	-	-	(52,041)	-
Total	合計	3,352,201	732,864	990,265	1,166,495	454,264	-	(52,041)	6,644,048
Segment profit	分部溢利	491,478	151,050	(89,280)	447,595	31,304	35,087	-	1,067,234
Depreciation of investment properties	投資物業之折舊								(2,603)
Unallocated other income, gains and losses	未分配其他收入、收益及虧損								(4,459)
Rental income of investment properties	投資物業之租金收入								5,830
Interest income from bank deposits	銀行存款之利息收入								77,356
Gain from changes in fair value of financial instruments at fair value through profit or loss	按公平值計入損益計量之金融工具公平值變動收益								(712)
Share of results of associates	應佔聯營公司業績								53,233
Share of results of joint ventures	應佔合營企業業績								(3,459)
Share-based payment expenses	以股份為基礎的付款開支								(4,910)
One-off expense related to value-added tax subsidy refunds	增值稅補助退還相關的 一次性支出								(34,539)
Gain on deemed disposal of investment in an associate	視作出售於一間聯營公司之 投資之收益								72,933
Profit before taxation	除稅前溢利								1,225,904

NOTES: (Continued)

3. Revenue and segment information

(Continued)

For the six months ended 30 June 2024
(Unaudited)

附註：(續)

3. 收入和分部資料 (續)

截至二零二四年六月三十日止六
個月 (未經審核)

		Medical device 醫療器械 RMB'000 人民幣千元	Orthopaedic 骨科 RMB'000 人民幣千元	Interventional 介入 RMB'000 人民幣千元	Pharma packaging 藥品包裝 RMB'000 人民幣千元	Blood management 血液管理 RMB'000 人民幣千元	Others 其他 RMB'000 人民幣千元	Eliminations 撇減 RMB'000 人民幣千元	Total 合計 RMB'000 人民幣千元
Revenue	收益								
External sales	外部銷售	3,292,636	744,991	1,010,341	1,167,605	420,115	-	-	6,635,688
Inter-segment sales	內部分部銷售	30,629	-	-	-	-	-	(30,629)	-
Total	合計	3,323,265	744,991	1,010,341	1,167,605	420,115	-	(30,629)	6,635,688
Segment profit	分部溢利	592,519	86,662	32,959	475,031	33,070	35,810	-	1,256,051
Depreciation of investment properties	投資物業之折舊								(2,807)
Unallocated other income, gains and losses	未分配其他收入、收益及虧損								(4,458)
Rental income of investment properties	投資物業之租金收入								5,706
Bank interest income	銀行利息收入								77,069
Gain from changes in fair value of financial instruments at fair value through profit or loss	按公平值計入損益計量之金融工具公平值變動收益								5,495
Share of results of associates	應佔聯營公司業績								47,633
Share of results of joint ventures	應佔合營企業業績								(6,865)
Share-based payment expenses	以股份為基礎的付款開支								(11,445)
Profit before taxation	除稅前溢利								1,366,379

NOTES: (Continued)**4. Finance costs**

Finance costs for the six months ended 30 June 2025 were approximately RMB116,773,000 (same period in 2024: approximately RMB128,776,000), which were mainly interest expenses on bank and other borrowings.

附註：(續)**4. 融資成本**

截至二零二五年六月三十日止六個月的融資成本約為人民幣116,773,000元(二零二四年同期：約為人民幣128,776,000元)，主要是銀行及其他借款的利息支出。

5. Profit before taxation**5. 除稅前溢利**

		Unaudited 未經審核 For the six months ended 30 June 截至六月三十日止六個月	
		2025 二零二五年 RMB'000 人民幣千元	2024 二零二四年 RMB'000 人民幣千元
Profit before taxation has been arrived at after charging (crediting) the followings:	除稅前溢利經扣除(計入)下列項目後達致：		
Allowances for credit losses	信貸虧損準備	12,595	7,490
Impairment losses on inventories	存貨減值虧損	28,949	13,687
Amortization of intangible assets	無形資產攤銷	145,118	130,612
Depreciation of property, plant and equipment	物業、廠房及設備折舊	314,930	301,407
Depreciation of investment properties	投資物業折舊	2,603	2,807
Depreciation of right-of-use assets	使用權資產折舊	23,439	20,541
Cost of inventories recognized as expenses	確認為開支的存貨成本	3,340,540	3,259,245
Staff costs, including directors' and supervisors' remuneration	員工成本(包括董事及監事薪酬)		
Retirement benefits scheme contribution	退休福利計劃供款	97,347	90,525
Salaries and other allowances	薪金及其他津貼	1,272,883	1,156,547
Share-based payment expenses	以股份為基礎的付款開支	13,022	18,290
Total staff costs	員工成本總額	1,383,252	1,265,362
Loss on disposal of property, plant and equipment	出售物業、廠房及設備虧損	1,292	210

NOTES: (Continued)

6. Income tax expense

Under the Law of the People's Republic of China on Enterprise Income Tax ("**EIT Law**") and Implementation Regulations of EIT Law, the tax rate of PRC subsidiaries is 25%.

In accordance with the Notice of the Ministry of Finance and the State Administration of Taxation Regarding Certain Preferential Treatment Policies on Enterprise Income Tax, new and high technology enterprises are subject to income tax at a tax rate of 15%.

The Company, Weihai Jierui Medical Products Company Limited (威海潔瑞醫用製品有限公司), Shandong Weigao Orthopaedic Device Company Limited ("**Weigao Orthopaedic**"), Weigao Medical Material Co., Ltd. (威海威高醫用材料有限公司), Weigao Jiesheng Medical Devices Co., Ltd. (威高潔盛醫療器械有限公司) and Shandong Weigao Puri Pharmaceutical Packaging Co., Ltd. (山東威高普瑞醫藥包裝有限公司) were recognized as Shandong Province New and High Technology Enterprises (山東省高新技術企業), Changzhou Jianli Bangde Medical Devices Co., Ltd. ("**Changzhou Jianli Bangde**") was recognized as Jiangsu Province New and High Technology Enterprises (江蘇省高新技術企業), and Zhejiang Liangzi Medical Devices Co., Ltd. (浙江量子醫療器械有限公司) was recognized as Zhejiang Province New and High Technology Enterprises (浙江省高新技術企業). Therefore, they are subject to income tax at a rate of 15%.

附註：(續)

6. 所得稅開支

根據《中華人民共和國企業所得稅法》(「**企業所得稅法**」)及《企業所得稅法實施條例》，中國附屬公司之稅率為25%。

根據《財政部國家稅務總局有關企業所得稅若干優惠政策的通知》，高新技術企業須按15%稅率繳付所得稅。

本公司、威海潔瑞醫用製品有限公司、山東威高骨科材料有限公司(「**威高骨科**」)、威海威高醫用材料有限公司、威高潔盛醫療器械有限公司、山東威高普瑞醫藥包裝有限公司獲確認為山東省高新技術企業，常州健力邦德醫療器械有限公司(「**常州健力邦德**」)獲確認為江蘇省高新技術企業，浙江量子醫療器械有限公司獲確認為浙江省高新技術企業，故彼等按15%稅率繳納所得稅。

NOTES: (Continued)

6. Income tax expense (Continued)

Jierui Subsidiary was recognised as a “Social Welfare Entity”. Pursuant to Cai Shui [2016] No. 52 issued by the Ministry of Finance and the State Administration of Taxation, with effect from 1 May 2016, Jierui Subsidiary is also subject to an income tax at a tax rate of 15% and an amount equivalent to the total salaries paid to staff with physical disability is further deducted from the assessable profit of Jierui Subsidiary. The tax charge provided for the period ended 30 June 2025 was made after taking these tax incentives into account.

Taxation for other PRC subsidiaries is computed at a tax rate of 25% (2024: 25%).

In the USA, the Group is subject to the Federal corporate income tax at a tax rate of 21% plus tax rate of state governments.

The Group is operating in certain jurisdictions where the Global Anti-base Erosion Rules (“**Pillar Two Rules**”) are effective or enacted but not effective. However, based on management’s best estimate, the management of the Group considered the Group is not liable to top-up tax under the Pillar Two Rules.

附註：(續)

6. 所得稅開支 (續)

潔瑞附屬公司獲確認為「社會福利企業」。根據財政部國家稅務總局發出之財稅[2016]第52號檔，由二零一六年五月一日起，潔瑞附屬公司亦須按15%稅率繳付所得稅，及相等於支付予殘障員工薪金總額之金額進一步自潔瑞附屬公司的應課稅溢利中扣減。截至二零二五年六月三十日止期間作出之稅項開支撥備已計及該等稅務優惠。

其他中國附屬公司的稅項乃按25%（二零二四年：25%）稅率計算。

於美國，本集團按聯邦企業所得稅稅率21%加各州政府稅率納稅。

本集團經營業務的若干司法權區已實施或已頒佈但未實施全球反稅基侵蝕規則（「**支柱二規則**」）。然而，根據管理層的最佳估計，本集團管理層認為本集團毋須根據支柱二規則繳納補足稅。

NOTES: (Continued)

7. Dividends

The Board recommends the distribution of an interim dividend of RMB0.0969 per share for the six months ended 30 June 2025 (same period in 2024: RMB0.0919 per share).

8. Earnings per share

For the six months ended 30 June 2025, basic earnings per share was calculated based on the net profits attributable to shareholders of approximately RMB1,008,317,000 (same period in 2024: approximately RMB1,107,549,000) and the weighted average total number of shares of 4,543,114,720 shares (same period in 2024: 4,507,876,324 shares).

For the six months ended 30 June 2025, diluted earnings per share was RMB0.22.

附註：(續)

7. 股息

董事會建議派發截至二零二五年六月三十日止六個月之中期股息每股人民幣0.0969元(二零二四年同期：每股人民幣0.0919元)。

8. 每股盈利

截至二零二五年六月三十日止六個月，每股基本盈利根據股東應佔純利約為人民幣1,008,317,000元(二零二四年同期：約為人民幣1,107,549,000元)及加權平均總股數4,543,114,720股(二零二四年同期：4,507,876,324股)計算。

截至二零二五年六月三十日止六個月，每股經攤薄盈利人民幣0.22元。

NOTES: (Continued)

9. Property, plant and equipment

附註：(續)

9. 物業、廠房及設備

		Construction in progress	Freehold land	Buildings	Plant and machinery	Motor vehicles	Furniture, fixtures equipment and tools	Total
		在建工程	完全擁有地權	建築物	廠房及機器	汽車	傢俱、固定裝置 及工具	總計
		RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
		人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元
COST	成本							
As at 31 December 2023	於二零二三年十二月三十一日	1,004,329	8,634	3,934,598	3,654,346	86,209	1,261,877	9,949,993
Additions	添置	422,662	-	479	188,273	8,499	103,733	723,646
Transfer	轉讓	(588,623)	-	92,296	459,753	41	36,533	-
Transfer from investment properties	轉撥自投資物業	-	-	21,978	-	-	-	21,978
Transfer to investment properties	轉撥至投資物業	-	-	(14,922)	-	-	-	(14,922)
Disposals	出售	-	-	(12,452)	(116,128)	(11,212)	(65,657)	(205,449)
Adjustment on exchange rate	匯率調整	1,100	255	2,368	5,926	66	2,604	12,319
As at 31 December 2024	於二零二四年十二月三十一日	839,468	8,889	4,024,345	4,192,170	83,603	1,339,090	10,487,565
Additions	添置	475,044	-	-	94,446	938	50,838	621,266
Transfer	轉讓	(96,568)	-	26,892	32,701	1,109	35,866	-
Transfer from investment properties	轉撥自投資物業	-	-	31,683	-	-	-	31,683
Disposals	出售	-	-	-	(20,313)	(594)	(45,206)	(66,113)
Adjustment on exchange rate	匯率調整	(706)	(172)	(1,445)	(4,641)	127	(2,471)	(9,308)
As at 30 June 2025 (Unaudited)	於二零二五年六月三十日 (未經審核)	1,217,238	8,717	4,081,475	4,294,363	85,183	1,378,117	11,065,093
DEPRECIATION	折舊							
As at 31 December 2023	於二零二三年十二月三十一日	12,455	-	924,062	1,677,038	52,512	771,503	3,437,570
Depreciation provided for the year	年內計提折舊撥備	-	-	135,105	319,571	7,456	166,138	628,270
Impairment provided for the year	年內計提減值撥備	173	-	-	-	-	-	173
Transfer from investment properties	轉撥自投資物業	-	-	3,299	-	-	-	3,299
Transfer to investment properties	轉撥至投資物業	-	-	(3,982)	-	-	-	(3,982)
Eliminated on disposals	於出售時抵銷	-	-	(1,478)	(43,434)	(9,765)	(61,257)	(115,934)
Adjustment on exchange rate	匯率調整	-	-	552	2,165	58	2,048	4,823
As at 31 December 2024	於二零二四年十二月三十一日	12,628	-	1,057,558	1,955,340	50,261	878,432	3,954,219
Impairment provided for the period	期內計提減值撥備	1,262	-	-	-	-	-	1,262
Provision for the period	期內撥備	-	-	75,030	169,543	3,556	66,801	314,930
Transfer from investment properties	轉撥自投資物業	-	-	7,548	-	-	-	7,548
Eliminated on disposals	於出售時抵銷	-	-	-	(15,461)	(436)	(40,310)	(56,207)
Adjustment on exchange rate	匯率調整	-	-	(432)	(1,612)	94	(1,342)	(3,292)
As at 30 June 2025 (Unaudited)	於二零二五年六月三十日 (未經審核)	13,890	-	1,139,704	2,107,810	53,475	903,581	4,218,460
CARRYING VALUES	賬面值							
As at 30 June 2025 (Unaudited)	於二零二五年六月三十日 (未經審核)	1,203,348	8,717	2,941,771	2,186,553	31,708	474,536	6,846,633
As at 31 December 2024 (Audited)	於二零二四年十二月三十一日 (已審核)	826,840	8,889	2,966,787	2,236,830	33,342	460,658	6,533,346

NOTES: (Continued)**10. Inventories****附註：(續)****10. 存貨**

Raw materials
Finished goods

原料
製成品

30 June 2025 二零二五年 六月三十日 RMB'000 人民幣千元 Unaudited 未經審核	31 December 2024 二零二四年 十二月三十一日 RMB'000 人民幣千元 Audited 已審核
510,034	663,619
1,774,354	1,864,806
2,284,388	2,528,425

11. Trade and other receivables**11. 應收貿易賬款及其他應收款項**

0 to 90 days
91 to 180 days
181 to 365 days
Over 365 days

0至90天
91至180天
181至365天
365天以上

Trade receivables
Receivables from factoring business
Other receivables
Prepayments

應收貿易賬款
保理業務應收款項
其他應收款項
預付款項

30 June 2025 二零二五年 六月三十日 Unaudited 未經審核 RMB'000 人民幣千元	31 December 2024 二零二四年 十二月三十一日 Audited 已審核 RMB'000 人民幣千元
2,909,628	3,201,138
1,248,361	1,185,534
1,474,877	928,260
848,275	763,447
6,481,141	6,078,379
237,372	209,704
758,363	852,976
769,134	745,064
8,246,010	7,886,123
8,196,613	7,832,235
49,397	53,888
8,246,010	7,886,123

Analysed for reporting purposes as:
Current assets
Non-current assets

就呈報目的分析為：
流動資產
非流動資產

NOTES: (Continued)

12. Pledged/restricted bank deposits

The amounts represented deposits pledged to banks to secure trade facilities granted to the Group and the issuance of letter of guarantee. The amounts had been pledged to secure against the short-term bank loans and bank credit facilities and are therefore classified as current assets. The bank deposits carry interest rates ranging from 0.05% to 1.1% (same period in 2024: 0.5% to 5.21%) per annum.

13. Bank balances and cash

Cash and cash equivalents

Cash and cash equivalents include demand deposits and short-term deposits for the purpose of meeting the Group's short term cash commitments, the interest rate of which ranges from 0.05% to 0.35% (same period in 2024: 0.15% to 1.05%) per annum.

Time deposits

The Group's time deposits were issued by banks with original maturity over three months, the interest rate of which ranges from 0.8% to 4.6% (same period in 2024: 1.05% to 5.5%) per annum.

附註：(續)

12. 已抵押／受限制銀行存款

該金額指已抵押予銀行的存款，用作抵押授予本集團的貿易融資及保函的開具。該金額已用作抵押短期銀行貸款及銀行信貸融資，故列為流動資產。該銀行存款的年利率介乎於0.05%至1.1%（二零二四年同期：0.5%至5.21%）之間。

13. 銀行結餘及現金

現金及現金等價物

現金及現金等價物包括用於滿足本集團短期現金承諾的活期存款及短期存款，該等存款的年利率介乎於0.05%至0.35%（二零二四年同期：0.15%至1.05%）之間。

定期存款

本集團的定期存款由銀行發行，原到期日為三個月以上，定期存款年利率介乎0.8%至4.6%（二零二四年同期：1.05%至5.5%）之間。

NOTES: (Continued)

14. Trade and other payables

附註：(續)

14. 應付貿易賬款及其他應付款項

		30 June 2025 二零二五年 六月三十日 Unaudited 未經審核 RMB'000 人民幣千元	31 December 2024 二零二四年 十二月三十一日 Audited 已審核 RMB'000 人民幣千元
0 to 90 days	0至90天	904,371	833,749
91 to 180 days	91至180天	119,473	122,226
181 to 365 days	181至365天	51,373	81,612
Over 365 days	365天以上	94,743	129,899
Trade payables	應付貿易賬款	1,169,960	1,167,486
Bills payable	應付票據	446,338	926,475
Other tax payables	其他應付稅項	91,494	44,386
Construction cost and retention payables	建築成本及應付保留金	106,708	48,503
Selling expense payables	應付銷售開支	841,852	846,875
Other payables	其他應付款項	1,451,790	1,440,126
Dividend payable	應付股息	218,224	—
		4,326,366	4,473,851
Analysed for reporting purposes as:	就呈報目的分析為：		
Current liabilities	流動負債	4,203,873	4,294,068
Non-current liabilities	非流動負債	122,493	179,783
		4,326,366	4,473,851

NOTES: (Continued)

15. Movement in reserves

附註：(續)

15. 儲備變動

		Share capital	Share premium reserve	Statutory surplus reserve	Translation reserve	Share-based payments reserve	Other reserves	Retained earnings	Non-controlling interests	Total
		股本	股份溢價	法定盈餘	匯兌儲備	以股份為基礎的儲備	其他儲備	保留盈餘	非控股權益	總計
		RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
		人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元
				Note						
				附註						
As at 1 January 2024 (Audited)	於二零二四年一月一日 (已審核)	457,063	2,743,144	261,271	216,114	275,604	(131,607)	18,627,532	22,449,121	23,992,705
Profit for the year	本年度溢利	-	-	-	-	-	-	2,066,668	2,066,668	2,162,716
Other comprehensive income for the year	年內其他全面收入	-	-	-	96,926	-	-	-	96,926	101,996
Total comprehensive income for the year	年內全面收入總額	-	-	-	96,926	-	-	2,066,668	2,163,594	2,264,712
Reduced upon vested of incentive shares	於激勵股份歸屬時削減	-	-	-	-	-	34,583	-	34,583	34,583
Recognition of equity-settled share-based payments	確認以權益結算之支付	-	-	-	-	34,677	-	-	34,677	1,343
Modification of share options	購股權之修訂	-	-	-	-	(69,145)	-	-	(69,145)	(7,845)
Repurchase of shares of a subsidiary	回購一間附屬公司股份	-	-	-	-	-	(21,820)	-	(21,820)	(43,476)
Dividends recognised as distribution	確認為分派的股息	-	-	-	-	-	-	(839,367)	(839,367)	(865,988)
Appropriation of statutory surplus reserve	提取法定盈餘儲備	-	-	2,415	-	-	-	(2,415)	-	-
As at 31 December 2024	於二零二四年十二月三十一日	457,063	2,743,144	263,686	313,040	241,136	(118,844)	19,852,418	23,751,643	25,341,566
Profit for the period	期內溢利	-	-	-	-	-	-	1,008,317	1,008,317	1,056,985
Other comprehensive income for the period	期內其他全面收入	-	-	-	(63,805)	-	-	-	(63,805)	(66,421)
Total comprehensive income for the period	期內全面收入總額	-	-	-	(63,805)	-	-	1,008,317	944,512	990,564
Recognition of equity-settled share-based payments	確認以權益結算之支付	-	-	-	-	10,805	-	-	10,805	2,217
Modification of share options	購股權之修訂	-	-	-	-	(3,903)	-	-	(3,903)	(4,345)
Acquisition of interests in subsidiaries from non-controlling shareholder	自非控股股東收購附屬公司權益	-	-	-	-	-	(1,296)	-	(1,296)	(17,973)
Repurchase of shares of the Company	回購本公司股份 (附註)	-	-	-	-	-	(41,339)	-	(41,339)	(41,339)
Dividends recognised as distribution	確認為分派的股息	-	-	-	-	-	-	(555,879)	(555,879)	(586,638)
As at 30 June 2025 (Unaudited)	於二零二五年六月三十日 (未經審核)	457,063	2,743,144	263,686	249,235	248,038	(161,479)	20,304,856	24,104,543	25,694,857

NOTES: (Continued)

15. Movement in reserves

Notes:

(A) BASES FOR APPROPRIATION TO RESERVES

Appropriation to statutory surplus reserve and statutory public welfare fund has been calculated based on the net profits in the financial statement prepared under the generally accepted accounting principles in the PRC ("**PRC GAAP**").

(B) STATUTORY SURPLUS RESERVE

The Articles of Association of the companies under the Group (other than overseas companies) requires that 10% of the profit after taxation for each year (prepared in accordance with the PRC GAAP) should be transferred to the statutory surplus reserve, until it has reached 50% of the registered capital. Pursuant to the Articles of Association of the companies under the Group, under normal circumstances, statutory surplus reserve can only be used to make up for the losses, converted into share capital by way of capitalisation, and for the expansion of the Company's production and operation scope. In the event of converting the statutory surplus reserve into share capital by way of capitalisation, the balance of such reserve shall not be less than 25% of the registered capital.

附註：(續)

15. 儲備變動

附註：

(A) 撥款至儲備的基準

轉撥至法定盈餘公積金和法定公益金，已根據按中國公認會計原則（「**中國公認會計原則**」）編製的財務報表所載純利計算。

(B) 法定盈餘公積金

本集團旗下公司（海外公司除外）的組織章程規定將其各年除稅後溢利（根據中國公認會計原則編製）的10%分派至法定盈餘公積金，直至法定盈餘公積金的結餘達註冊股本的50%為止。根據本集團旗下公司的組織章程的條文規定，在一般情況下，法定盈餘公積金僅可用作彌補虧損、撥充股本及擴充本公司之生產及營運。將法定盈餘公積金撥充股本後，該公積金的餘額不得低於註冊股本的25%。

NOTES: (Continued)

15. Movement in reserves (Continued)

Notes: (Continued)

(C) STATUTORY PUBLIC WELFARE FUND

According to the Company Law of the PRC and the amended Articles of Association of the Company, from 1 January 2006 onwards, the companies under the Group ceased to transfer funds from statutory public welfare fund. The statutory public welfare fund as of 31 December 2005 was part of the share capital of the shareholders, which cannot be distributed other than for the purpose of liquidation. Pursuant to the board resolution of the Company, in accordance with the Company Law of the PRC, the Company transferred an amount of RMB17,147,000 from statutory public welfare fund to the statutory surplus reserve on 1 January 2006.

附註：(續)

15. 儲備變動 (續)

附註：(續)

(C) 法定公益金

根據中國公司法和經修改後的本公司章程，由二零零六年一月一日起，本集團轄下各公司毋須提取法定公益金。而於截至二零零五年十二月三十一日止提取的法定公益金為股東股本的一部分，但除於清盤外，不得分配。根據本公司董事會決議，按照中國公司法，本公司將於二零零六年一月一日的法定公益金人民幣17,147,000元轉移至法定盈餘公積金。

NOTES: (Continued)

15. Movement in reserves (Continued)

Notes: (Continued)

(D) REPURCHASE OF SHARES OF THE COMPANY

Pursuant to the resolutions of the shareholders passed at the annual general meeting of the Company (the “AGM”) held 28 May 2024, the Company granted a general mandate to its directors to repurchase shares of the Company not exceeding 10% of the aggregate nominal value of H Shares in issue (excluding any treasury shares). During the interim period, 8,132,400 ordinary shares have been repurchased with par value of RMB0.1 each, with a total consideration of HKD44,659,000 (approximately RMB41,339,000), at prices ranging from HKD4.62 to HKD6.15 per share.

According to the laws and regulations of the PRC, the distributable profit of the Company was determined at the lower of such amount computed based on the accounting principles and regulations of the PRC or the generally accepted accounting principles in Hong Kong. As of 30 June 2025, the retained earnings available for distribution to shareholders was approximately RMB10,074,000,000.

附註：(續)

15. 儲備變動 (續)

附註：(續)

(D) 回購本公司股份

根據本公司於二零二四年五月二十八日舉行的股東週年大會（「股東週年大會」）上通過的股東決議案，本公司授予其董事一般授權，以回購不超過已發行H股總面值（不包括任何庫存股）10%的本公司股份。於中期期間，已購回8,132,400股每股面值人民幣0.1元的普通股，總代價為44,659,000港元（約人民幣41,339,000元），每股價格介乎4.62港元至6.15港元。

根據中國的法律及條例，本公司可供分派的利潤，以按照中國會計準則及條例或按照香港公認會計準則所報列金額中的較低者為基準，截至二零二五年六月三十日，可供分配予股東的保留盈利約為人民幣10,074,000,000元。

MANAGEMENT DISCUSSION AND ANALYSIS

Optimisation and Upgrade of Business Segments

During the Period, the gross profit margin of the Group decreased from 50.9% for the corresponding period of last year to 49.7%, showing a month-on-month stabilization. The Group proactively responded to national and regional volume-driven procurements by lowering the selling prices of some of the products. The impact of such price cuts on gross profit margin was partially offset by the Group's reduction in production costs. Moreover, the impact of volume-driven procurements on operating profit was offset by the reduction in operating expenses. The product mix of the Group was further adjusted and optimised, thus further enhancing its risk resistance capability. Looking forward into the future, the Group will continue to enrich its product mix, and leverage the strong scalable strengths of the Company to continue maintaining and further increasing its dominant market position.

The existing major products of the Group under each business line are as follows:

- The medical device business products include clinical care, anesthesia, surgical-related products and medical testing equipment
- The orthopaedic business products include trauma, spinal implant, artificial joints, sports injury, soft tissue repair, reconstruction implant, orthopaedic filling, and orthopaedic related surgical tools

管理層討論與分析

業務領域優化升級

期間內，本集團毛利率水準從去年同期的50.9%下降到49.7%，環比企穩。集團積極應對國家和區域帶量採購，部分產品的銷售價格有所降低。集團積極降低生產成本，部分抵消降價對毛利率的影響；此外，通過優化運營費用，抵消了帶量採購對經營利潤的影響。集團產品結構進一步調整和優化，抗風險能力進一步加強。著眼未來，本集團會持續豐富產品組合，並憑借公司強大的規模實力，繼續保持並進一步提升於該市場的優勢地位。

本集團各業務領域現有主要產品如下：

- 醫療器械業務產品包括：臨床護理、麻醉及手術相關產品、醫學檢驗器械
- 骨科業務產品包括：創傷、脊柱植入物，人工關節，運動損傷、軟組織修復及重建植入物、骨填充材料、骨科相關手術工具

- Interventional business products include tumor intervention, vascular intervention, and interventional imaging
 - The pharmaceutical packaging business products include prefilled syringes, pre-filled flush syringes and automatic dosing device products
 - The blood management business products include blood collection, storage, separation, and sterilization of consumables and equipment
- 介入業務產品包括：腫瘤介入、血管介入、影像介入
 - 藥品包裝業務產品包括：預灌封注射器、沖管注射器以及自動給藥裝置產品
 - 血液管理業務產品包括：血液採集、貯存、分離、滅菌消毒耗材及設備
1. During the Period, medical device products recorded a turnover of approximately RMB3,190,538,000, representing an increase of 0.1% over the corresponding period. The Group seized the opportunity of volume-driven procurements of different products in various provinces to quickly increase its sales volume and market share. Revenue from the perioperative product portfolio demonstrated a significant growth, effectively offsetting the impact of volume-based procurements on the revenue.
 1. 期間內，醫療器械產品錄得營業額約為人民幣3,190,538,000元，較同期增長0.1%。不同的產品在各省陸續被帶量採購，本集團抓住機會，快速增加銷量，提升市場份額。圍手術期系列產品組合收入顯著增長，有力抵消帶量採購對收入的影響。

2. During the Period, the orthopaedic business products recorded a turnover of approximately RMB732,864,000, representing a decrease of 1.6% over the corresponding period of last year. Facing the continued deepening of the policy impact and the new stage of industry reshaping, we grasped the opportunity for change and continued to push forward the transformation of the sales model, with significant improvement in the terminal service capability, continuing increase in customer coverage and growth in terminal surgical implantation.
2. 期間內，骨科業務產品錄得營業額約為人民幣732,864,000元，較去年同期下降1.6%。面對政策影響的持續加深和行業重塑的新階段，我們把握變革機遇，持續推進銷售模式轉型，終端服務能力顯著提升，客戶覆蓋持續增加，終端手術植入量也得到增長。
3. During the Period, the interventional business products recorded a turnover of approximately RMB1,099,887,000, representing a decrease of 1.3% over the corresponding period of last year. Global business progressed in a steady manner, and the customer coverage in China continued to increase with great potential.
3. 期間內，介入業務產品錄得營業額約為人民幣1,099,887,000元，較去年同期下降1.3%。全球業務穩步推進，中國客戶覆蓋持續增長，且潛力巨大。
4. During the Period, the pharmaceutical packaging business products recorded a turnover of approximately RMB1,166,495,000, representing a decrease of 0.1% over the corresponding period of last year. The stable demand for prefilled syringes further expanded its market influence in the pre-pack bio-pharmaceuticals segment and formed a broad customer base. Sales of automatic dosing device increased rapidly, which will drive the continued growth in this business in the future.
4. 期間內，藥品包裝業務產品錄得營業額約為人民幣1,166,495,000元，較去年同期下降0.1%。預灌封注射器需求穩定，進一步擴大在生物製藥包裝領域的市場影響力，形成廣泛客戶基礎。自動給藥裝置銷量快速提升，未來將拉動該業務持續增長。

RESEARCH AND DEVELOPMENT

For the six months ended 30 June 2025, the Group had 63 new patents and 146 patents are under application in the PRC. New product registration certificates for 63 products were obtained. The research and development for 51 products were completed for which applications for product registration certificates are underway. For overseas market, 55 new patents are under application and the research and development for 27 products were completed for which application for product registration certificates are underway.

The strategy of placing strong emphasis on research and development has enhanced the Company's core competitiveness and laid a solid foundation to fully leverage on its customer resources and also provided the Group with continuous new profit growth drivers.

As at 30 June 2025, the Group had 927 product registration certificates and 1,084 patents, of which 218 were patents on invention, in the PRC. For overseas market, the Group had 905 product registration certificates and 156 patents.

研究與開發

截至二零二五年六月三十日止六個月，本集團中國國內新增專利63項，正在申請中的146項，新增產品註冊證63項，已經研發完成、尚在取證過程中的產品註冊證有51項。海外，正在申請中的專利55項，已經研發完成、尚在取證過程中的產品註冊證有27項。

注重研發的經營策略提升了公司的核心競爭力，並為充分利用客戶資源夯實了產品基礎，亦為集團持續盈利提供了新的增長點。

於二零二五年六月三十日，本集團國內擁有927項產品註冊證，1,084項專利，其中218項是發明專利。海外，擁有905項產品註冊證，156項專利。

In view of the need for the strategic adjustments to product mix, the Group continued to invest in the research and development in existing products series and several new medical devices, so as to further improve its product mix under sub-classification of medical devices product types. For the six months ended 30 June 2025, total research and development expenses amounted to approximately RMB315,532,000 (same period in 2024: approximately RMB301,613,000), representing 4.7% (same period in 2024: 4.5%) of the revenue of the Group.

PRODUCTION

During the Period, the Group continued to increase its investment in capacity expansion and production facilities based on market demand and long-term development plans. We focused on introducing advanced equipment such as high-performance automated equipment, AI visual inspection, and high-efficiency moulds. Through adding intelligent production lines for core products, we not only significantly improved production efficiency but also realized the optimization and upgrading of production processes with significant improvement in automation and intelligence levels, successfully achieving a transition to high-tech processing and manufacturing. In terms of cost control, manufacturing costs have significantly decreased. By improving the supply chain to reduce material costs, combined with labour savings and manufacturing cost control measures, we ensured the implementation of “cost reduction, efficiency improvement, and quality assurance initiatives”. This has ultimately safeguarded the stability and enhancement of the Company’s overall profitability, laying a solid foundation for expanding market share through enhanced production capacity and cost advantage, and further strengthening the core competitiveness of its products.

基於產品結構戰略性調整的要求，本集團繼續保持在現有產品系列和多個新醫療器械領域的研發投入，以進一步完善醫療器械細分領域的產品組合。截至二零二五年六月三十日止六個月，研發之總開支約為人民幣315,532,000元（二零二四年同期：約為人民幣301,613,000元），佔本集團收入的4.7%（二零二四年同期：4.5%）。

生產

期內，本集團圍繞市場需求與長期發展規劃，持續加大產能建設及生產設施投入。重點聚焦高性能自動化設備、AI視覺檢測、高效率模具等先進裝備的引入。通過新增核心產品智能化生產線、不僅大幅提升了生產效率，實現了生產流程的優化與升級，在提升自動化、智能化水平方面成效顯著，成功實現了向高科技加工製造的轉變。在成本管控方面，製造成本顯著下降。通過供應鏈改善降低物料成本，結合人工節約，製造費用管控等手段，確保「降本，增效，保質」工作落地實施，最終保障公司整體盈利能力的穩定與提升，為後續拓展市場份額奠定了堅實的產能與成本優勢，進一步提升了產品的核心競爭力。

SALES AND MARKETING

The Group continues to implement the strategy in integrating its sales channels and adjusting its product mix. Domestically, we accelerate grassroots market layout, whilst focusing on high-potential markets for comprehensive development overseas. For the six months ended 30 June 2025, the Group newly added 64 hospitals, 77 distributors to its PRC customer base. As at the publication date of this report, the Group has a PRC customer base of 10,307 in aggregate (including 4,062 hospitals, 419 blood stations, 1,204 other medical units and 4,622 distributors) and an overseas customer base of 7,513 in aggregate (including 3,333 hospitals, 1,870 other medical units and 2,310 distributors).

銷售及市場推廣

本集團繼續堅持銷售渠道整合與產品結構調整之策略。國內加快基層市場佈局，海外聚焦潛力市場全面拓展。截至二零二五年六月三十日止六個月，本集團國內客戶新增64家醫院，77家經銷商。於本報告刊發日期，本集團的國內客戶總數為10,307家（包括醫院4,062家、血站419家、其他醫療單位1,204家和經銷商4,622家），海外客戶總數為7,513家（包括醫院3,333家、其他醫療單位1,870家和經銷商2,310家）。

Information about the Group's revenue from external customers is presented based on the location of the customers. Sales proportion for various products by geographical regions when compared with the same period last year is set out as follows:

本集團來自外部客戶之收入之資料乃按客戶位置呈列。各種產品在不同地區的銷售佔比及與去年同期對比如下：

Turnover by Geographical Locations

營業收入地區分佈

		Unaudited For the six months ended 30 June 未經審核 截至六月三十日止六個月				Over corresponding period 較同期
Regions	地區	2025 二零二五年		2024 二零二四年		%
		RMB'000 人民幣千元	% 佔比%	RMB'000 人民幣千元	% 佔比%	
The PRC	國內					
– Eastern and Central	— 華東與華中	2,615,195	39.4	2,706,381	40.8	(3.4)
– Northern	— 華北	886,491	13.3	955,085	14.4	(7.2)
– Southern	— 華南	604,369	9.1	502,560	7.6	20.3
– Northeast	— 東北	418,128	6.3	419,626	6.3	(0.4)
– Southwest	— 西南	377,238	5.7	382,870	5.8	(1.5)
– Northwest	— 西北	118,896	1.8	107,589	1.6	10.5
PRC sub-total	國內小計	5,020,317	75.6	5,074,111	76.5	(1.1)
Overseas	海外					
– The US	— 美國	723,702	10.9	670,525	10.1	7.9
– Asia and others	— 亞洲及其他	487,345	7.3	508,089	7.6	(4.1)
– Europe, Middle East and Africa	— 歐洲、中東及非洲	412,684	6.2	382,963	5.8	7.8
Overseas sub-total	海外小計	1,623,731	24.4	1,561,577	23.5	4.0
Total	總計	6,644,048	100.0	6,635,688	100.0	0.1

Comparison of sales revenue of principal products with that in the same period last year is as follows:

		Unaudited For the six months ended 30 June 未經審核 截至六月三十日止六個月		Over corresponding period 較同期 %
Product category	產品類別	2025 二零二五年 RMB'000 人民幣千元	2024 二零二四年 RMB'000 人民幣千元	
Medical device product	醫療器械產品	3,190,538	3,188,625	0.1
Orthopaedic product	骨科產品	732,864	744,991	(1.6)
Interventional product	介入產品	1,099,887	1,114,352	(1.3)
Pharma packaging product	藥品包裝產品	1,166,495	1,167,605	(0.1)
Blood management product	血液管理產品	454,264	420,115	8.1
Total	總計	6,644,048	6,635,688	0.1

HUMAN RESOURCES

As at 30 June 2025, the Group employed a total of 13,063 employees. The breakdown by departments when compared with last year is as follows:

人力資源

於二零二五年六月三十日，本集團共聘用13,063名僱員，與去年比較的部門分析如下：

Department	部門	As at 30 June 2025 於 二零二五年 六月三十日	As at 31 December 2024 於 二零二四年 十二月三十一日
Production	生產	6,755	6,440
Sales and marketing	銷售及市場推廣	3,225	3,180
Research and development	研發	1,373	1,386
Finance and administration	財務及行政	637	622
Quality control	質量控制	662	650
Management	管理	352	354
Purchasing	採購	59	87
Total	總計	13,063	12,719

A total of 1,175 overseas employees reside in the US, Europe and Hong Kong. Other employees of the Group reside in Mainland China. During the Period, total cost of salaries, welfare and social benefits of the Group amounted to approximately RMB1,383,252,000 (same period in 2024: approximately RMB1,265,362,000).

合共海外僱員1,175名於美國、歐洲、香港等地居住，本集團的其他僱員均位於中國內地。期間內，本集團在員工薪資、福利、社會保障等的成本總額約為人民幣1,383,252,000元（二零二四年同期：約為人民幣1,265,362,000元）。

Remuneration System

The Group's remuneration policy has been determined based on its performance, local consumption power and competition in human resources market. The remuneration policy so determined has become the basis of determining the salary level of employees recruited for different positions. The salary of each employee is determined according to the employee's performance, ability, employment conditions and the salary standards set by the Company. Remuneration of Directors is proposed by the Remuneration Committee with reference to the operating results of the Company, personal performance of the Directors and market competition. The remuneration of Directors is determined by the Board subject to approval by shareholders at the annual general meeting.

FINANCIAL REVIEW

For the six months ended 30 June 2025, the turnover reached approximately RMB6,644,048,000, representing an increase of approximately 0.1% over the same period last year. Net profit attributable to owners of the Company was approximately RMB1,008,317,000, representing a decrease of approximately 9.0% as compared to the same period last year.

Net profit attributable to the owners of the Company (excluding extraordinary items) was approximately RMB967,095,000, representing a decrease of approximately 12.7% as compared to comparable figure (same period in 2024: approximately RMB1,107,549,000) over the same period last year. (Note)

薪酬訂立制度

本集團的薪酬政策是根據其表現，本地的消費水準和人力資源市場競爭狀況釐定。該釐定的薪酬政策作為聘任不同崗位僱員薪資水準的基準。每位僱員的薪資視乎僱員的表現、能力、任職條件及本公司的預定薪資標準而定。董事的酬金是由薪酬委員會經參考本公司的經營業績、董事個人表現及市場競爭情況的基礎上制定薪酬方案，並經股東於股東週年大會上授權董事會釐定。

財務回顧

截至二零二五年六月三十日止六個月，營業額達至約為人民幣6,644,048,000元，較去年同期增長約0.1%。錄得本公司擁有人應佔純利約為人民幣1,008,317,000元，較去年同期下跌約9.0%。

不計特殊項目的本公司擁有人應佔純利約人民幣967,095,000元，較去年同期可比數（二零二四年同期：約人民幣1,107,549,000元）下跌約12.7%。（註）

Note: the extraordinary items for the Period were:

註：期間內，特殊項目為：

- (1) The Company's equity interest in Shandong Weigao Blood Purification Products Co., Ltd. ("**Weigao Blood Purification**") was diluted from 26.55% to 23.90%, which is due to the public offering of new shares by Weigo Blood Purification, and generated a gain of approximately RMB72,933,000.

- (1) 山東威高血液淨化製品股份有限公司（「**威高血液淨化**」）公開發行新股，本公司由26.55%攤薄至23.90%形成收益約人民幣72,933,000元。

- (2) One-off expenditure of RMB31,711,000.

- (2) 一 次 性 費 用 支 出 人 民 幣 31,711,000元。

Liquidity and Financial Resources

The Group has maintained a sound financial position. As at 30 June 2025, the Group's cash and bank balance amounted to approximately RMB8,945,180,000. For the six months ended 30 June 2025, net cash flow from operating activities of the Group amounted to approximately RMB881,573,000, representing a sound cash flow position.

Total interest expenses of the Group for the six months ended 30 June 2025 were approximately RMB116,773,000 (same period in 2024: approximately RMB128,776,000).

流動資金及財務資源

本集團維持良好的財務狀況。於二零二五年六月三十日，本集團現金及銀行結餘約為人民幣8,945,180,000元。截至二零二五年六月三十日止六個月，本集團經營活動現金流量淨額約為人民幣881,573,000元，現金流量狀況健康。

截至二零二五年六月三十日止六個月，本集團的整體利息支出總額約為人民幣116,773,000元（二零二四年同期：約為人民幣128,776,000元）。

Gearing Ratio

As at 30 June 2025, the gearing ratio of the Group was 22.9% (31 December 2024: 17.7%). The gearing ratio represents total debt as a percentage of total capital. Total debt is calculated as total borrowings and bonds payable. Total capital is calculated as the equity attributable to owners of the Company.

Foreign Exchange Risks

The Group's purchases and sales are mainly conducted in the PRC and the United States. Assets, liabilities and transactions in the PRC are denominated in RMB, while overseas assets and transactions are mainly denominated in US dollars. Foreign exchange risk mainly arises from unsettled borrowings denominated in foreign currencies. The Group has adopted foreign currency hedging instruments to achieve better foreign exchange risk management. The objective of the hedge is to minimise the volatility of the RMB expenditures expected to be incurred in the future to meet foreign currency liabilities. The Group's risk management policy is to partially hedge the forecasted cash flows in foreign currencies by considering the appropriate hedging instruments and costs of hedging. The Group uses foreign exchange structured derivative financial contracts to hedge its foreign currency risk. For the six months ended 30 June 2024, the Group had not encountered any material difficulty due to currency fluctuation nor had it affected its funds for operation purpose.

Due to the fluctuation in exchange rates, foreign exchange loss equivalent to RMB58,230,000 (same period in 2024: foreign exchange gain equivalent to RMB19,970,000) for the six months ended 30 June 2025 was recorded by the Company.

資本負債比率

於二零二五年六月三十日，本集團之資本負債比率為22.9%（二零二四年十二月三十一日：17.7%）。資本負債比率指債務總額與資本總額之百分比。債務總額乃按借貸及應付債券總額計算。資本總額乃按本公司擁有人應佔權益計算。

匯率風險

本集團的採購和銷售以中國、美國兩地為主。中國境內資產、負債及交易以人民幣計值，海外資產及交易主要以美元計值，外匯風險主要來源於未結清的外幣借貸。本集團已採用了外幣對沖工具來達到更好的外匯風險管理。對沖保值的目標在於使預計未來可能發生的償還外幣負債需要的人民幣支出的波動性最小化。本集團的風險管理政策是在考慮合適的對沖工具以及對沖的成本後，部分對沖外幣預測現金流量。本集團通過外匯結構性衍生金融合同來對沖外匯風險。截至二零二四年六月三十日止六個月，本集團並無因匯率波動而遇到重大困難或自身的營運資金受到影響。

由於匯率波動，本公司在截至二零二五年六月三十日止六個月形成匯兌損失折合人民幣58,230,000元（二零二四年同期：匯兌收益折合人民幣19,970,000元）。

Material Investments in Subsidiaries/ Future Material Investment Plans

1. During the Period, the Group continued to invest approximately RMB433,605,000 in the purchase of property, production facilities and plant construction for the purpose of enhancing the overall construction of the industrial zone for the Group's medical consumables.
2. The Group planned to invest RMB770,000,000 to acquire the 38.5% interest in the Songyuan Healthcare Industry Fund (松源健康醫療產業基金), which focuses on the investments in the medical and healthcare sector mainly covering medical devices, biopharmaceuticals, medical services and rehabilitation and elderly care, of which a total of RMB308,000,000 has been contributed.
3. During the Period, a new production line for pre-filled syringes and a production line for auto-injectors with a planned investment of approximately RMB250,000,000 is under construction and is expected to be successively put into operation in 2026.
4. During the Period, construction was underway for the planned investment of approximately RMB340,000,000 for upgrading and reconfiguration of the single-use consumables and orthopaedic consumables production equipment to further enhance the level of production automation.

重大附屬公司投資／未來重大投資計劃

1. 期間內，本集團繼續投資約人民幣433,605,000元，用於購置物業、生產設備與建設廠房，為完善本集團醫療耗材工業園整體建設之用。
2. 本集團計劃出資人民幣770,000,000元投資松源健康醫療產業基金，佔比38.5%，該基金重點投資於以醫療器械、生物製藥、醫藥服務、康復養老為主的醫療健康領域，已累計出資人民幣308,000,000元。
3. 期間內，計劃投資約人民幣250,000,000元的預灌封注射器新產線及自動注射筆產線正在建設中，預計二零二六年可陸續投入生產。
4. 期間內，計劃投入約人民幣340,000,000元的一次性耗材及骨科耗材設備更新改造項目已在實施中，會進一步提升生產的自動化水平。

5. In January 2023, Weigao Orthopaedic, a subsidiary of the Company acquired 100% equity interest in Shandong Weigao Newlife Medical Device Co., Ltd., a fellow subsidiary of the Company, which is principally engaged in the research and development, manufacture and sale of tissue repair product lines, at a consideration of RMB1,030,000,000. The transfer price is payable in instalments, with RMB103,000,000 is expected to be paid in the second half of the year.

5. 二零二三年一月，本公司附屬公司威高骨科以人民幣1,030,000,000元收購本公司同系附屬公司山東威高新生醫療器械有限公司100%股權，該公司主要從事組織修復產品線的研發、製造及銷售。轉讓價款分期支付，預計下半年支付人民幣103,000,000元。

Save for the above material investments and investment plans, the Group had no any future plans involving significant investments or capital assets acquisition as at 30 June 2025.

除上述重大投資與投資計劃外，於二零二五年六月三十日，本集團並無參與重大投資或購入資本資產之未來計劃。

Capital Commitment

As at 30 June 2025, the capital commitment that the Group and the Company had contracted for but not provided in the financial statements amounted to approximately RMB1,030,768,000 (same period in 2024: approximately RMB1,179,123,000).

資本承擔

於二零二五年六月三十日，本集團及本公司已經簽約，但尚未於財務報表中作出撥備的資本承擔約為人民幣1,030,768,000元（二零二四年同期：約為人民幣1,179,123,000元）。

REVIEW & OUTLOOK

In the first half of 2025, the Group proactively responded to changes in the domestic medical industry and continued to advance its internationalised strategy layout, maintaining a stable growth momentum across its overall business.

In the domestic market, the diagnosis demand for medical institutions exhibited regional disparities and hierarchical difference, bringing both challenges and new development opportunities. Benefiting from continuous product innovation and channel optimization, the Group's core business segments achieved year-on-year sales growth. The Company's perioperative product portfolio for generic medical devices, which was launched since the end of last year, achieved rapid revenue growth.

In light of the in-depth facilitation of the centralized volume-based procurement policy for medical devices, certain products not subject to centralized procurement were gradually included in bulk procurement, exerting phasal pressure on the revenue growth of related business lines. To tackle such challenge, the Group improved its supply chain management through various measures, successfully reducing costs while intensifying its efforts in market expansion to propel a rapid growth in sales of related products.

回顧與展望

2025年上半年，本集團積極應對國內醫療行業變化，持續推進國際化戰略佈局，整體業務保持穩健發展態勢。

在國內市場方面，醫療機構診療需求呈現區域分化和層級差異，這既帶來了挑戰，也創造了新的發展機遇。得益於持續的產品創新和渠道優化，集團核心業務板塊銷量實現同比增長。公司自去年底佈局的通用醫療器械圍術期系列產品組合實現較快收入增長。

面對醫療器械集中帶量採購政策的深入推進，部分未進行集採產品逐步參與帶量採購，對相關業務線的收入增速造成階段性壓力。為應對這一挑戰，本集團通過多種措施開展供應鏈管理改進工作，成功實現成本降低，同時加大市場拓展力度，推動相關產品銷量實現較快增長。

In the international market, the foreign operation continued to maintain its growth momentum. We progressively focused on target markets, integrated local resources, and comprehensively expanded the markets of Weigao's superior products in the countries or regions where we operate. We devised a comprehensive planning and steady promotion in exporting our core products. Our subsidiary in USA continued to extend the product portfolio to achieve phasal results in exploring and expanding the application of existing technologies in new business areas.

It should be noted that there was no significant drop in US dollar interest rate, while overseas finance costs remained at a relative high level. Since the beginning of the year, the US dollar index has weakened, resulting in exchange losses. In responding to this, we took proactive foreign exchange risk management measures for hedging. The prolonged accounts receivable period of some domestic medical institutions increased operating costs and lowered asset turnover efficiency. To address this, the Group strengthened its internal management mechanisms and cooperated with financial institutions to shorten the collection cycle.

在國際市場方面，海外業務繼續保持增長勢頭。逐步聚焦目標市場、整合當地資源、全面拓展威高優勢產品在所在國家或地區的市場。核心產品製造出海全面規劃、穩步推進。美國子公司不斷延伸產品組合，探索和拓展已有技術在新業務領域的應用取得階段性成果。

需要指出的是，美元利率未發生顯著下降，境外融資成本保持較高水平；年初以來美元指數走弱，形成匯兌損失。為此，我們採取了積極的外匯風險管理措施進行對沖。部分國內醫療機構客戶應收賬款賬期延長增加了運營成本、降低資產周轉效率。針對這一情況，本集團通過強化內部管理機制及與金融機構合作縮短回款週期。

The generic medical device segment recorded stable revenue in the first half year. Despite continuous promotion of the centralized procurement of some products, the price decrease was narrowing down. By facilitating the growth of new product portfolios, the segment boasted strong capabilities to counter risks. At the same time, the Company made proactive deployment in common consumption market development and seized opportunities to expand its market share rapidly and enhanced its competitiveness in the industry.

In the orthopedic segment, facing the new stage of industry reshaping, we proactively adjusted marketing strategies and marketing structures and continued to facilitate sales model transformation. Our terminal service capabilities improved significantly and customer coverage continued to expand. Integrating with the market and technology development trend as well as clinical feedback, we closely centered on the innovation needs brought by changes in clinical surgical methods to expand our product lines, and focused on research and development innovations in areas such as minimally invasive spinal surgery, sports medicine, and orthopedic repair and regeneration.

通用醫療器械板塊，上半年收入企穩。儘管部分產品的集採繼續推進，但價格降幅趨於收窄。憑借推動新的產品組合上量，表現出有較強的風險應對能力。同時積極佈局基層市場開拓，抓住機會，提升市場份額，增強行業競爭力。

骨科板塊，面對行業重塑的新階段，積極調整營銷策略及營銷架構，持續推進銷售模式轉型，終端服務能力顯著提升，客戶覆蓋持續增加。結合市場、技術發展趨勢和臨床反饋，緊緊圍繞臨床手術方式變化帶來的創新需求進行產線的拓展佈局，聚焦脊柱微創、運動醫學和骨科修復再生等進行研發創新。

In the pharmaceutical packaging business, our market position has been further reinforced. Customer loyalty was strengthened by continuously increasing production capacity to enhance its ability to serve downstream pharmaceutical manufacturers. The Group also grasped the opportunities from downstream enterprise products, business layout and product upgrading to expand sales and actively expand pharmaceutical packaging product portfolio. Auto-injectors and pen injectors witnessed a robust growth in terms of their sales volume since their launch.

In the interventional segment, revenue was stable in the first half year. With continuous new product arrangements and quickly introduced them into the markets, the revenue increased. The thrombus removal system (Cleaner Vac) was widely used in clinical academic activities in the USA and received positive market feedback.

藥品包裝板塊，市場地位進一步鞏固。通過持續提升產能，加強對下游製藥企業的服務能力，提高客戶黏性。把握下游企業產品、業務佈局及產品升級的機會提高銷量並積極擴充藥品包裝產品組合。自動注射筆及筆試注射器上市後銷量強勁增長。

介入板塊，上半年收入平穩。隨着持續佈局新產品並快速推向市場拉動收入增長。血栓清除系統(Cleaner Vac)在美國開展廣泛的臨床學術活動，得到市場積極反饋。

As a leading medical device enterprise in China, the Group is committed to providing medical institutions with total solutions in various professional segments to help them improve their diagnostic and treatment capabilities and standards. The Group continued to expand and enrich its product portfolios in various specialty areas such as perioperative series, urology series, self-administration drug delivery systems, orthopedic sports medicine, biomaterials, minimally invasive spinal surgery, vascular intervention for deep vein thrombosis.

The Group continued to improve and enhance corporate governance and propel strategies for sustainable development to facilitate long-term and high-quality development. The Group highlights responsible operation and meets public demands for medical products with high-quality products. The Company stresses the green development concept and implements concepts, goals and initiatives in relation to energy conservation and emission reduction in operation.

The Group formulates development strategies and medium and long-term development plans on a rolling basis. Taking into account the changes in industry policies and the competitive landscape, clinical requirements and its own internal resources reserves, the Company proposed a three-pronged operational strategy of “platform-based”, “internationalised” and “digitalised” development and dual assurance strategies underpinned by “talents” and “innovation”. The Company intends to deliver long-term and stable value through the implementation of such strategies.

作為中國醫療器械領先企業，本集團致力為醫療機構提供多專業領域的整體解決方案，協助其提升診療能力和水平。本集團持續拓展和豐富圍手術期系列、泌尿系列、自我給藥系統、骨科運動醫學、生物材料、脊柱微創等系列、血管介入深靜脈血栓等各專科領域的產品組合。

本集團持續完善、提升治理水平，推行可持續發展策略，助力長期高質量發展。強調負責任經營，以優質的產品滿足社會對醫療產品的需求。強調綠色發展理念，將節能減排的理念、目標和行動措施，貫穿到公司運營中去。

本集團滾動制定發展戰略和中長期發展規劃。結合行業政策和競爭格局的變化、臨床需求、自身資源的積累等情況，提出「平台化」、「國際化」、「數字化」三大經營戰略和「人才」、「創新」兩大保障戰略。通過戰略的貫徹和實施創造長期穩健的價值。

The management believes that on the back of its strategic presence in a wide range of business sectors and high-quality products, an operational strategy underpinned by persistent market adaptation and a future-oriented approach and initiatives that motivate employee creativity, the Group will continue to maintain and strengthen its leading position in the PRC market. Meanwhile, the Company will actively promote global resource sharing to achieve synergistic development in the domestic and foreign markets to support the stable growth of the Group's operating results.

PROPOSED INTERIM DIVIDEND

The Board recommended the distribution of an interim dividend of RMB0.0969 per share (corresponding period in 2024: RMB0.0919 per share) for the six months ended 30 June 2025. Such proposal is subject to the approval by the shareholders of the Company (the “**Shareholders**”) at the forthcoming extraordinary general meeting (“**Extraordinary General Meeting**”) to be held on Thursday, 16 October 2025.

管理層相信，憑借廣泛的業務領域戰略佈局及高質量產品，堅持適應市場、面向未來的經營策略，激發員工創造性，本集團將繼續保持並加強中國市場領先地位。同時積極推動全球資源共享，實現國內外市場協同發展，支持本集團經營業績穩健增長。

建議中期股息

董事會建議派發截至二零二五年六月三十日止六個月之中期股息每股人民幣0.0969元（二零二四年同期：每股人民幣0.0919元）。該建議須經本公司股東（「**股東**」）在即將於二零二五年十月十六日（星期四）舉行的股東特別大會（「**股東特別大會**」）上批准後，方可作實。

EXTRAORDINARY GENERAL MEETING AND CLOSURE OF REGISTER OF MEMBERS

Attending and Voting in the Extraordinary General Meeting

In order to determine the shareholders who are entitled to attend and vote at the Extraordinary General Meeting, the register of members of the Company for H Shares will be closed from Monday, 13 October 2025 to Thursday, 16 October 2025 (both days inclusive), during which period no transfer of H Shares will be effected. In order to qualify for attending and voting in the Extraordinary General Meeting, Shareholders should ensure that all transfer documents, accompanied by the relevant share certificates, are lodged with the Company's H Share registrar, Tricor Investor Services Limited, at 17/F., Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration no later than 4:30 p.m. on Friday, 10 October 2025.

股東特別大會及暫停辦理股份過戶登記手續 出席股東特別大會並於會上投票

為釐定有權出席股東特別大會並於會上投票的股東，本公司將於二零二五年十月十三日（星期一）至二零二五年十月十六日（星期四）（首尾兩日包括在內）暫停H股過戶登記，於該期間將不會辦理H股過戶登記手續。為符合資格出席股東特別大會並於會上投票，股東應確保所有過戶文件連同有關股票不遲於二零二五年十月十日（星期五）下午四時三十分送交本公司的H股過戶登記處卓佳證券登記有限公司，地址為香港夏慤道16號遠東金融中心17樓，以辦理登記手續。

In order to qualify for attending the Extraordinary General Meeting:-

為符合資格出席股東特別大會：—

Latest time to lodge in the

transfer instrument accompanied

by the share certificates 4:30 p.m., Friday,
10 October 2025

交回過戶文件連同股票之最後時限 二零二五年十月十日（星期五）
下午四時三十分

Closure of register of members of
the Company for attendance

of the Extraordinary General Meeting Monday, 13 October 2025 to
Thursday, 16 October 2025

本公司就出席股東特別大會

暫停股份過戶登記 二零二五年十月十三日（星期一）
至二零二五年十月十六日（星期四）

Date of Extraordinary General Meeting Thursday, 16 October 2025

股東特別大會日期 二零二五年十月十六日（星期四）

Entitlement of Interim dividend

In order to determine the entitlement to the interim dividend payment, the register of members of the Company for H Shares will be closed from Wednesday, 22 October 2025 to Friday, 24 October 2025 (both days inclusive), during which period no transfer of H Shares will be effected. In order to qualify for entitlement of the interim dividend, holders of H Shares should ensure that all transfer documents, accompanied by the relevant share certificates, are lodged with the Company's H Share registrar, Tricor Investor Services Limited, at 17/F., Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration no later than 4:30 p.m. on Tuesday, 21 October 2025.

In order to qualify for the interim dividend for the six months ended 30 June 2025:

Latest time to lodge in the transfer instrument

accompanied by the share certificates

交回過戶文件連同股票之最後時限

Closure of register of members of the Company for

entitlement of interim dividend

本公司暫停股份過戶登記

以釐定中期股息之權利

中期股息之權利

為確定收取中期股息付款之權利，本公司將於二零二五年十月二十二日（星期三）至二零二五年十月二十四日（星期五）（首尾兩日包括在內）暫停H股過戶登記，於該期間將不會辦理H股過戶登記手續。為符合資格收取中期股息，H股持有人應確保所有過戶文件連同有關股票不遲於二零二五年十月二十一日（星期二）下午四時三十分送交本公司之H股過戶登記處卓佳證券登記有限公司，地址為香港夏慤道16號遠東金融中心17樓，以辦理登記手續。

為符合資格獲派截至二零二五年六月三十日止六個月之中期股息：

4:30 p.m., Tuesday,
21 October 2025

二零二五年十月二十一日（星期二）
下午四時三十分

Wednesday, 22 October 2025 to
Friday, 24 October 2025

二零二五年十月二十二日（星期三）
至二零二五年十月二十四日（星期五）

Record date for entitlement of

interim dividend Friday, 24 October 2025
釐定中期股息權利之記錄日期 二零二五年十月二十四日 (星期五)

Despatch date of interim dividend Friday, 21 November 2025
中期股息寄發日期 二零二五年十一月二十一日 (星期五)

The interim dividend will be despatched at the risk of those entitled thereto to their respective registered addresses on or around Friday, 21 November 2025. The applicable exchange rate for converting RMB into Hong Kong dollar for the purpose of the interim dividend payment will be based on the average middle exchange rate of Renminbi as quoted by the People's Bank of China for the calendar week preceding 16 October 2025, the date on which the interim dividend to be declared.

中期股息將於二零二五年十一月二十一日 (星期五) 或前後按有權獲派中期股息之持有人各自之登記地址寄發予彼等，郵誤風險由彼等自行承擔。就中期股息付款之人民幣兌港元之適用匯率將以於二零二五年十月十六日 (即宣派中期股息之日) 前一個日曆週中國人民銀行發佈的人民幣平均匯率中間價為準。

INCENTIVE SHARE SCHEME

The Company adopted an incentive share scheme on 17 November 2014 (“**Incentive Share Scheme**”). The purposes of the Incentive Share Scheme are to: (i) enable the Company to provide incentive to the Eligible Participants (as defined below) in order to recognise and motivate the contributions they have made or will make to the Group; (ii) attract and retain quality talents for the business operation, management and development of the Group; (iii) align the interests of the management, the employees and the Group to ensure the realisation of the Group’s development strategy and business objectives; and (iv) attain a long-term relationship between the Group and its employees.

Subject to the relevant requirements under the Listing Rules, Eligible Participants are persons eligible to receive awards under the Incentive Share Scheme include any employee (whether full-time or part-time, but excluding any Excluded Employee as defined under the Incentive Share Scheme) of any member of the Group, or any person who, in the sole opinion of the remuneration committee of the Company, will contribute or has contributed to any member of the Group. The maximum number of the issuable Shares under the specific mandate of Incentive Share shall not exceed 223,818,616 Shares, representing 5% of the number of Shares in issue on the date of adoption of the Incentive Share Scheme.

激勵股份計劃

本公司於二零一四年十一月十七日採納一項激勵股份計劃（「**激勵股份計劃**」）。激勵股份計劃的目的為：(i)使本公司向合資格參與者（定義見下文）授予股票作為激勵及獎勵其為集團已作出或將作出的貢獻；(ii)為本集團的業務經營、管理及發展吸引及挽留優秀人才；(iii)將管理團隊的利益、員工利益與本集團利益結合起來，保證本集團發展戰略和經營目標的實現；及(iv)建立本集團與員工之間長期的穩定關係。

在上市規則相關要求的規限下，合資格參與者指根據激勵股份計劃合資格獲得獎勵的人士，包括任何本集團成員公司的任何全職或兼職的僱員，但不包括激勵股份計劃界定的任何除外人員，或由本公司薪酬委員會全權認為將會或曾經對任何本集團成員公司作出貢獻的任何人士。激勵股份特別授權項下可發行股份數目最多將不超過223,818,616股，佔採納激勵股份計劃日期已發行股份數目的5%。

The Company issued 94,260,000 Shares in total under the specific mandate. As at 30 June 2025, 129,558,616 outstanding Shares remain available to issue under the specific mandate, representing approximately 2.83% of the total issue share capital of the Company. The maximum number of Shares that may be granted to the Eligible Participant selected by the remuneration committee of the Company to participate in the Incentive Share Scheme (“**Selected Employees**”) must not exceed 0.5% of the issued share capital of the Company at the date of the grant. The length of the vesting period, vesting and other conditions (such as the length of the lock-up period) that must be satisfied for the exercise of the subscription right will be determined by the remuneration committee of the Company at its discretion, and may vary among the Selected Employees depending on their position, length of service with the Group and performance. No exercise period for awarded shares was set. The Selected Employees can exercise the share awards in anytime upon vesting. Save for the subscription price, participants are not required to pay any amount upon participation of the Incentive Share Scheme. The subscription price represents the net asset value per Share as set out in the audited consolidated financial statements of the Company in the last financial year immediately preceding the grant date of the share awards. Subject to an early termination of the Incentive Share Scheme as determined by the Remuneration Committee, the Incentive Share Scheme will be effective for a term of 10 years commencing from the date of adoption of the Incentive Share Scheme, until 16 November 2024.

本公司根據特別授權合共已發行94,260,000股股份。於二零二五年六月三十日，129,558,616股未發行股份仍可根據特別授權發行，佔本公司已發行股本總額約2.83%。可授予由本公司薪酬委員會指定參加激勵股份計劃的合資格參與者（「**受益人**」）的股份最高數目不得超過本公司於授出日期已發行股本的0.5%。就行使認購權而須達致的歸屬期限、歸屬及其他條件（如鎖定期）將由本公司薪酬委員會酌情釐定，並視乎受益人的狀況、於本集團的服務年期及表現而有所不同。獎勵股份並無設定行使期。受益人可於歸屬後隨時行使股份獎勵。除認購價外，參與者在參加激勵股份計劃時無需支付任何金額。認購價代表本公司於緊接股份獎勵授出日期前最近財政年度之經審核合併財務報表所載每股淨資產價值。於薪酬委員會決定提前終止激勵股份計劃的情況下，激勵股份計劃之有效期自激勵股份計劃採納日期起至二零二四年十一月十六日止，為期10年。

Details of the movement of the share awards granted pursuant to the Incentive Share Scheme during the Period were as follows:

期間內，根據激勵股份計劃授予的股份獎勵變動詳情如下：

Name of grantee	Date of grant	Number of share awards 股份獎勵數目					Exercisable as at 30 June 2025	Subscription price upon grant	Weighted average closing price of the shares immediately before the dates the awards were exercised or vested 股份於緊接 獎勵獲行使 或歸屬日期前 的加權平均 收市價
		Exercisable as at 1 January 2025 於二零二五年 一月一日 可行使	Vested during the Period 期間內已歸屬	Exercised during the Period 期間內已行使	Cancelled during the Period 期間內已註銷	Lapsed during the Period 期間內已失效			
承授人姓名	授出日期						於二零二五年 六月三十日 可行使	授出時之 認購價 (RMB) (人民幣)	(HKD) (港元)
Directors									
董事									
Mr. Long Jing 龍經先生	11/12/2015 (batch 1)	480,000	-	-	-	-	480,000	2.2	5.59
	11/12/2015 (第一批)								
	24/12/2021 (batch 2)	4,800,000	-	-	-	-	4,800,000	3.58	9.48
	24/12/2021 (第二批)								
Mr. Cong Rinan 龔日楠先生	11/12/2015 (batch 1)	200,000	-	-	-	-	200,000	2.2	5.59
	11/12/2015 (第一批)								
	24/12/2021 (batch 2)	1,600,000	-	-	-	-	1,600,000	3.58	9.49
	24/12/2021 (第二批)								
Mr. Wang Daoming 王道明先生	24/12/2021 (batch 2)	400,000	-	-	-	-	400,000	3.58	6.86
	24/12/2021 (第二批)								
Other Eligible Participants									
其他合資格參與者									
employees 僱員	11/12/2015 (batch 1)	430,000	-	-	-	-	430,000	2.2	5.59
	11/12/2015 (第一批)								
	24/12/2021 (batch 2)	31,840,000	-	-	-	-	31,840,000	3.58	9.50
	24/12/2021 (第二批)								

Notes:

附註：

1. With respect to batch 1 of the share awards granted in 2015, a total of 1,110,000 shares were exercisable as at 30 June 2025. Such shares, together with (i) 8,812,000 shares that were repurchased by the trustee upon exercise by the directors and employees; and (ii) 4,534,000 shares that were lapsed and retained by the trustee pursuant to the Incentive Share Scheme, represents the total outstanding incentive shares of 14,456,000 held by the trustee for the benefit of the Incentive Share Scheme (batch 1).
2. The number of share awards and the shares are calculated on a 1:1 basis (i.e. 1 share award = 1 Shares).
1. 就二零一五年授出的第一批股份獎勵而言，於二零二五年六月三十日，合共1,110,000股股份可行使。有關股份，連同(i)董事及僱員行使後由受託人回購的8,812,000股股份；及(ii)根據激勵股份計劃已失效且由受託人保留的4,534,000股股份，代表受託人為激勵股份計劃（第一批）的利益持有的合共14,456,000股未行使激勵股份。
2. 股份獎勵及股份的數目乃按一比一基準（即1份股份獎勵=1股股份）計算。

DISCLOSURE OF INTERESTS

Directors' and Chief Executives' Interests and Short Position

As at 30 June 2025, the interests and short positions of the Directors and the chief executive of the Company in the shares, underlying shares and debentures of the Company or of any associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (the “SFO”)) of the Company, which will have to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which he is taken or deemed to have under such provisions of the SFO) or which will be required, as recorded in the register maintained by the Company pursuant to Section 352 of the SFO, or as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers (the “Model Code”) as contained in Appendix C3 to the Rules Governing the Listing of Securities on the Stock Exchange (the “Listing Rules”) were as follows:

權益披露

董事及主要行政人員的權益及淡倉

於二零二五年六月三十日，董事及本公司主要行政人員於本公司或本公司任何相聯法團（定義見證券及期貨條例（「證券及期貨條例」）第XV部）的股份、相關股份及債權證中，擁有根據證券及期貨條例第XV部第7及第8分部將須知會本公司及聯交所的權益及淡倉（包括根據證券及期貨條例有關條文當作或視為擁有的權益及淡倉），或根據證券及期貨條例第352條將須登記於本公司存置的登記冊的權益及淡倉，或根據聯交所證券上市規則（「上市規則」）附錄C3所載上市發行人董事進行證券交易的標準守則（「標準守則」）另行知會本公司及聯交所的權益及淡倉如下：

(i) Long positions in the shares and underlying shares of the Company:

(i) 於本公司股份及相關股份的好倉：

Name of director	Nature of interest	Capacity	Number of H Shares held	% of H Shares in issue (Note 1)	Number of Domestic Shares held	% of Domestic Shares in issue (Note 1)	% of the total issued share capital of the Company (Note 1)
							佔本公司已發行股本總額百分比 (附註1)
董事姓名	權益性質	身份	所持H股數目	佔已發行H股百分比 (附註1)	所持內資股數目	佔已發行內資股百分比 (附註1)	佔本公司已發行股本總額百分比 (附註1)
Mr. Long Jing (Note 2) 龍經先生 (附註2)	Personal 個人	Beneficial Owner 實益擁有人	480,000	0.0106	6,000,000	12.42	0.1420
Mr. Cong Rinan (Note 3) 叢日楠先生 (附註3)	Personal 個人	Beneficial Owner 實益擁有人	200,000	0.0044	2,000,000	4.14	0.0482
Mr. Wang Daoming (Note 4) 王道明先生 (附註4)	Personal 個人	Beneficial Owner 實益擁有人	-	-	500,000	1.04	0.0110
Mr. Chen Lin 陳林先生	Personal 個人	Beneficial Owner 實益擁有人	196,000	0.0043	-	-	0.0043

Note:

附註：

- As at 30 June 2025, the number of total issued shares of the Company was 4,562,499,924, comprising 4,514,199,924 H Shares (excluding 8,132,400 treasury shares) and 48,300,000 Domestic Shares.

- 於二零二五年六月三十日，本公司已發行股份總數為4,562,499,924股，包括4,514,199,924股H股（不包括8,132,400股庫存股份）及48,300,000股內資股。

- | | |
|--|--|
| <p>2. The interest disclosed represents (i) Mr. Long's personal interest in 480,000 H Shares; and (ii) 6,000,000 Domestic Shares granted pursuant to the Incentive Share Scheme.</p> | <p>2. 所披露權益指(i)龍先生於480,000股H股中的個人權益；及(ii)根據激勵股份計劃授出的6,000,000股內資股。</p> |
| <p>3. The interest disclosed represents (i) Mr. Cong's personal interest in 200,000 H Shares; and (ii) 2,000,000 Domestic Shares granted pursuant to the Incentive Share Scheme.</p> | <p>3. 所披露權益指(i)叢先生於200,000股H股中的個人權益；及(ii)根據激勵股份計劃授出的2,000,000股內資股。</p> |
| <p>4. The relevant interests are Domestic Shares granted pursuant to the Incentive Share Scheme.</p> | <p>4. 相關權益為根據激勵股份計劃授出的內資股。</p> |

(ii) Long positions in the shares and underlying shares of the associated corporations of the Company

(ii) 於本公司相聯法團之股份及相關股份的好倉

Name of director	Name of associated corporation	Capacity/ Nature of interest	Amount of equity interest held	% of interest in the associated corporation 於相聯法團權益之百分比
董事姓名	相聯法團名稱	身份／權益性質	所持股權數額	
Mr. Chen Lin	(1) Weihai Weigao International Medical Investment Holding Co., Ltd.(Note i)	Beneficial owner	RMB1,100,800	6.90%
陳林先生	威海威高國際醫療投資控股有限公司(附註i)	實益擁有人	人民幣1,100,800元	
	(2) Weigao Holding Company Limited(Note i)	Beneficial owner	RMB9,760,000	0.81%
	威高集團有限公司(附註i)	實益擁有人	人民幣9,760,000元	
Mr. Lu Junqiang	Shandong Weigao Orthopaedic Device Company Limited	Beneficial Owner	400,000 A shares (Note ii)	0.10%
盧均強先生	山東威高骨科材料股份有限公司	實益擁有人	400,000股A股(附註ii)	

Notes:

- (i) Weihai Weigao International Medical Investment Holding Co., Ltd. (“**Weihai Weigao International**”) holds 89.93% equity interest in Weigao Holding Company Limited (“**Weigao Holding**”), which is the controlling shareholder of the Company.
- (ii) These underlying shares were incentive share options granted to Mr. Lu Junqiang and were vested pursuant to the share award scheme of Shandong Weigao Orthopadeic Device Company Limited, a subsidiary of the Company listed on the Shanghai Stock Exchange.

Save as disclosed above, as at 30 June 2025, none of the Directors and chief executive of the Company had any interests or short position in the shares and underlying shares of the Company or any of its associated corporations (within the meaning of the SFO) which (a) were required to be notified to the Company and the Stock Exchange pursuant to Part XV of the SFO (including the interests and short positions which the Director is taken or deemed to have under such provisions of the SFO); or (b) were required, pursuant to section 352 of the SFO, to be entered in the register referred to therein; or (c) were required, pursuant to the Model Code to be notified to the Company and the Stock Exchange.

附註：

- (i) 威海威高國際醫療投資控股有限公司（「**威海威高國際**」）持有本公司控股股東威高集團有限公司（「**威高集團**」）89.93%股權。
- (ii) 該等相關股份為授予盧均強先生並根據山東威高骨科材料股份有限公司（本公司於上海證券交易所上市之附屬公司）之股份獎勵計劃歸屬之激勵購股權。

除上文所披露者外，於二零二五年六月三十日，概無董事及本公司主要行政人員於本公司或其任何相聯法團（定義見證券及期貨條例）的股份及相關股份中，擁有(a)根據證券及期貨條例第XV部須知會本公司及聯交所的權益或淡倉（包括根據證券及期貨條例有關條文董事被當作或視為擁有的權益及淡倉）；或(b)根據證券及期貨條例第352條須登記於該條所指登記冊的權益或淡倉；或(c)根據標準守則須知會本公司及聯交所的權益或淡倉。

Substantial Shareholders

As at 30 June 2025, so far as the Directors are aware, the following persons (other than the Directors and the chief executive of the Company) or institutions have interests or short positions of 5% or more in the shares or underlying shares of the Company as recorded in the register required to be kept under section 336 of the SFO:

主要股東

於二零二五年六月三十日，就董事所知，按證券及期貨條例第336條而須存置之登記冊所記錄，下列人士（董事及本公司主要行政人員除外）或機構擁有本公司股份或相關股份5%或以上之權益或淡倉：

Name of shareholder	Nature of interest	Number of H Shares held (Note 2)	% of total issued H share capital (Note 1) 佔已發行 H股股本 總額百分比 (附註1)
股東名稱	權益性質	所持H股數目 (附註2)	
Mr. Chen Xueli 陳學利先生	Interest of controlled corporation 受控法團權益	2,099,755,676 (L)	46.51
Weihai Weigao International 威海威高國際	Interest of controlled corporation 受控法團權益	2,099,755,676 (L)	46.51
Weigao Holding 威高集團	Beneficial owner 實益擁有人	1,982,755,676 (L)	43.92
	Interest of controlled corporation 受控法團權益	117,000,000 (L)	2.59
Wego International Capital Holding Corporation Limited 威高國際資本有限公司	Beneficial owner 實益擁有人	117,000,000 (L)	2.59

Notes:

附註：

1. As at 30 June 2025, the number of total issued shares of the Company was 4,562,499,924, comprising 4,514,199,924 H Shares (excluding 8,132,400 treasury shares) and 48,300,000 Domestic Shares.
1. 於二零二五年六月三十日，本公司已發行股份總數為4,562,499,924股，包括4,514,199,924股H股（不包括8,132,400股庫存股份）及48,300,000股內資股。
2. Wego International Capital Holding Corporation Limited (“**Wego Capital**”) is 100% owned by Weigao Holding. The Company is owned as to 46.51% by Weigao Holding, which is 89.83% owned by Weihai Weigao International. Weihai Weigao International is 50.80% owned by Mr. Chen Xueli. Accordingly, Mr. Chen Xueli and Weihai Weigao International are deemed to be interested in the shares of the Company held by Weigao Holding and Wego Capital for the purpose of Part XV of the SFO.
2. 威高國際資本有限公司（「**威高資本**」）由威高集團持有100%權益。本公司由威高集團持有46.51%權益，而威高集團由威海威高國際持有89.83%權益。威海威高國際由陳學利先生持有50.80%權益。因此，根據證券及期貨條例第XV部，陳學利先生及威海威高國際被視為於威高集團及威高資本所持本公司股份中擁有權益。

Save as disclosed above, as at 30 June 2025, no other persons (other than the Directors and chief executives of the Company) had any interests or short positions in the shares or underlying shares of the Company as recorded in the register required to be kept under section 336 of the SFO.

除上文所披露者外，於二零二五年六月三十日，概無其他人士（董事及本公司主要行政人員除外）於本公司的股份或相關股份中擁有根據證券及期貨條例第336條而須存置之登記冊所記錄的任何權益或淡倉。

MAJOR CUSTOMERS AND SUPPLIERS

During the Period, the combined value of the Group's contracts with its five largest suppliers, which were not of a capital nature, was less than 30 per cent of the total value of supplies purchased. The Group's five largest customers combined contributed less than 30 per cent of its total revenue and other income during the Period.

主要客戶及供應商

本期間內，本集團與其五大供應商的合約總值（不屬於資本性質者）佔所採購的供應品總值少於30%。本集團五大客戶合共佔其本期間內收入及其他收益總額少於30%。

During the Period, none of the Directors, their associates or any shareholders (which to the knowledge of the Director owned more than 5% of the Company's issued share capital) has a beneficial interest in the Group's five largest customers or suppliers.

CORPORATE GOVERNANCE

The Board is committed to high standards of corporate governance and recognises that good governance is vital for the long-term success and sustainability of the Group's businesses. The Company has adopted the code provisions as set out in the Corporate Governance Code (the "**Code**") contained in Appendix C1 to the Listing Rules. For the six months ended 30 June 2025, the Company has complied with all the code provisions as set out in the Code.

MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers ("**Model Code**") as set out in Appendix C3 of the Listing Rules as the standard for securities transactions by Directors. The Company had made specific enquiry of all Directors whether they have complied with the required standard set out in the Model Code during the six months ended 30 June 2025 and all Directors confirmed that they have complied with the Model Code during the six months ended 30 June 2025.

本期間內，本公司董事、其聯繫人或據董事所知擁有本公司已發行股本5%以上的任何股東概無於本集團五大客戶或供應商中擁有實益權益。

企業管治

董事會致力維持高水準的企業管治，並深信良好的管治對本集團業務的長遠成功及可持續發展至為關鍵。本公司已採納上市規則附錄C1內《企業管治守則》（「**守則**」）所載的守則條文。截至二零二五年六月三十日止六個月，本公司一直遵守守則所載的所有守則條文。

董事進行證券交易的標準守則

本公司已採納上市規則附錄C3所載的《上市發行人董事進行證券交易的標準守則》（「**標準守則**」），作為董事進行證券交易的準則。本公司已就董事於截至二零二五年六月三十日止六個月有否遵守標準守則所載的規定標準向全體董事作出具體查詢，而全體董事已確認彼等於截至二零二五年六月三十日止六個月均遵守標準守則。

AUDIT COMMITTEE

The audit committee of the Company currently comprises four independent non-executive Directors, being Mr. Li Guohui (chairman of the audit committee), Mrs. Meng Hong, Mr. Li Qiang and Mr. Sun Heng; and one non-executive Director, being Mr. Tang Zhengpeng. The audit committee has reviewed the unaudited consolidated financial statement of the Company for the six months ended 30 June 2025 and considered that the relevant financial statements have been prepared in compliance with the applicable accounting principles and requirements of the Stock Exchange and other laws, and adequate disclosures have been made.

審核委員會

本公司審核委員會目前由四名獨立非執行董事即李國輝先生（審核委員會主席）、孟紅女士、李強先生及孫恆先生；及一名非執行董事即湯正鵬先生組成。審核委員會已審閱本公司截至二零二五年六月三十日止六個月之未經審核綜合財務報表，且認為相關財務報表乃根據適用的會計原則以及聯交所及其他法律規定編製，並已作出適當披露。

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

During the six months ended 30 June 2025, the Company repurchased a total of 8,132,400 H shares of the Company ("H Shares") on the Stock Exchange. Details of the repurchases of shares are as follows:

購買、出售或贖回本公司上市證券

截至二零二五年六月三十日止六個月，本公司於聯交所購回合共 8,132,400 股本公司 H 股（「H 股」）。購回股份的詳情載列如下：

Month	月份	Number of H Shares repurchased 購回H股 數目	Price per H Shares 每股H股價格		Aggregate price (before expenses) 價格總額 (未計費用) HK\$'000 千港元
			Highest 最高 HK\$ 港元	Lowest 最低 HK\$ 港元	
February	二月	2,086,000	5.12	4.62	10,408
April	四月	2,944,800	6.10	5.16	16,374
May	五月	1,797,600	5.99	5.52	10,430
June	六月	1,304,000	6.15	5.23	7,447
		8,132,400			44,659

Subsequently, the Company repurchased a total of 677,200 H Shares in July 2025 at the aggregate price of approximately HK\$3,998,000 (before expenses).

其後本公司於二零二五年七月購回合共677,200股H股，價格總額約為3,998,000港元（未計費用）。

All the repurchased H Shares are held as treasury shares.

全部購回H股均作為庫存股份持有。

Save as disclosed above, neither the Company, nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed securities during the six months ended 30 June 2025.

除上文所披露外，截至二零二五年六月三十日止六個月，本公司及其任何附屬公司概無購買、出售或贖回任何本公司之上市證券。

ARRANGEMENTS TO PURCHASE SHARES OR DEBENTURES

購買股份或債券的安排

At no time during the Period was the Company, its ultimate holding company or any subsidiaries of its ultimate holding company, a party to any arrangements to enable the Directors to acquire benefits by means of the acquisition of shares in, or debentures of, the Company or any other body corporate.

本公司、其最終控股公司或其最終控股公司的任何附屬公司於期間內概無訂立任何安排，以致董事可藉購入本公司或任何其他法人團體的股份或者債券而獲益。

EVENTS AFTER THE REPORTING PERIOD

There have been no significant events occurring after the end of the reporting period and up to the date of this report.

By Order of the Board

**Shandong Weigao Group Medical
Polymer Company Limited**

Long Jing

Chairman

27 August 2025

Weihai, Shandong, the PRC

報告期後事項

於報告期末後及直至本報告日期，概無發生任何重大事項。

承董事會命

**山東威高集團醫用高分子製品股份有
限公司**

董事長

龍經

二零二五年八月二十七日

中國山東省威海市

As at the date of this report, the Board comprises:

於本報告刊發日期，董事會成員包括：

Mr. Long Jing (*Executive Director*)

Mr. Cong Rinan (*Executive Director*)

Mr. Lu Junqiang (*Executive Director*)

Mr. Wang Daoming (*Executive Director*)

Ms. Yan Xia (*Non-executive Director*)

Mr. Chen Lin (*Non-executive Director*)

Mr. Tang Zhengpeng (*Non-executive Director*)

Mr. Li Guohui

(*Independent Non-executive Director*)

Mrs. Meng Hong

(*Independent Non-executive Director*)

Mr. Li Qiang (*Independent Non-executive Director*)

Mr. Sun Heng

(*Independent Non-executive Director*)

龍經先生 (*執行董事*)

叢日楠先生 (*執行董事*)

盧均強先生 (*執行董事*)

王道明先生 (*執行董事*)

燕霞女士 (*非執行董事*)

陳林先生 (*非執行董事*)

湯正鵬先生 (*非執行董事*)

李國輝先生

(*獨立非執行董事*)

孟紅女士

(*獨立非執行董事*)

李強先生 (*獨立非執行董事*)

孫恆先生

(*獨立非執行董事*)

***WEGO* 威高**



This interim report is printed on environmental paper
此中期報告以環保紙張印製